Amyloid- \hat{I}^2 and Tau

JAMA Neurology 71, 505 DOI: 10.1001/jamaneurol.2013.5847

Citation Report

#	Article	IF	CITATIONS
1	Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta. Experimental Cell Research, 1975, 95, 263-268.	1.2	12
2	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs. Journal of Alzheimer's Disease, 2013, 34, 1-114.	1.2	23
3	Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities. Frontiers in Aging Neuroscience, 2014, 6, 306.	1.7	59
4	The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. Frontiers in Cellular Neuroscience, 2014, 8, 282.	1.8	25
5	Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration. Frontiers in Cellular Neuroscience, 2014, 8, 314.	1.8	293
6	Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. Frontiers in Molecular Neuroscience, 2014, 7, 40.	1.4	21
7	Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells. Drug Design, Development and Therapy, 2014, 9, 241.	2.0	18
8	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014. Journal of Alzheimer's Disease, 2014, 42, 1079-1149.	1.2	5
9	Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Molecular Neurodegeneration, 2014, 9, 46.	4.4	42
10	Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurology, 2014, 14, 169.	0.8	59
11	Neuroinflammation in Alzheimer's Disease: from Pathogenesis to a Therapeutic Target. Journal of Clinical Immunology, 2014, 34, 64-69.	2.0	86
12	The Pancreas-Brain Axis: Insight into Disrupted Mechanisms Associating Type 2 Diabetes and Alzheimer's Disease, Journal of Alzheimer's Disease, 2014, 42, 347-356.	1.2	31
13	Integration of multiscale dendritic spine structure and function data into systems biology models. Frontiers in Neuroanatomy, 2014, 8, 130.	0.9	14
14	PSEN1 and PSEN2 Gene Expression in Alzheimer's Disease Brain: A New Approach. Journal of Alzheimer's Disease, 2014, 42, 757-760.	1.2	28
15	MicroRNA-34a induces apoptosis in PC12 cells by reducing B-cell lymphoma 2 and sirtuin-1 expression. Molecular Medicine Reports, 2015, 12, 5709-5714.	1.1	14
16	Aggregation of MBP in chronic demyelination. Annals of Clinical and Translational Neurology, 2015, 2, 711-721.	1.7	40
17	Regulation of human MAPT gene expression. Molecular Neurodegeneration, 2015, 10, 28.	4.4	132
18	Long-term Dantrolene Treatment Reduced Intraneuronal Amyloid in Aged Alzheimer Triple Transgenic Mice, Alzheimer Disease and Associated Disorders, 2015, 29, 184-191	0.6	38

#	Article	IF	CITATIONS
19	Dysregulation of Amyloid-β Protein Precursor, β-Secretase, Presenilin 1 and 2 Genes in the Rat Selectively Vulnerable CA1 Subfield of Hippocampus Following Transient Global Brain Ischemia. Journal of Alzheimer's Disease, 2015, 47, 1047-1056.	1.2	60
20	Exposure to general anesthesia and the risk of dementia. Journal of Pain Research, 2015, 8, 711.	0.8	18
21	The Possible Roles of the Dentate Granule Cell's Leptin and Other Ciliary Receptors in Alzheimer's Neuropathology. Cells, 2015, 4, 253-274.	1.8	4
22	Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease. Frontiers in Aging Neuroscience, 2015, 7, 130.	1.7	81
23	Role of diffuse low-level heteroplasmy of mitochondrial DNA in Alzheimer's disease neurodegeneration. Frontiers in Aging Neuroscience, 2015, 7, 142.	1.7	26
24	Fragile X mental retardation protein: from autism to neurodegenerative disease. Frontiers in Cellular Neuroscience, 2015, 9, 43.	1.8	20
25	Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimerââ,¬â"¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 65.	1.8	70
26	The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Frontiers in Neuroscience, 2015, 9, 184.	1.4	34
27	Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. Frontiers in Neuroscience, 2015, 9, 198.	1.4	52
28	Cerebral small vessel disease and Alzheimer's disease. Clinical Interventions in Aging, 2015, 10, 1695.	1.3	81
29	Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease. PLoS ONE, 2015, 10, e0120194.	1.1	53
30	Toxicant Exposure and Bioaccumulation: A Common and Potentially Reversible Cause of Cognitive Dysfunction and Dementia. Behavioural Neurology, 2015, 2015, 1-10.	1.1	44
31	C-Reactive Protein Induces Tau Hyperphosphorylation via GSK3β Signaling Pathway in SH-SY5Y Cells. Journal of Molecular Neuroscience, 2015, 56, 519-527.	1.1	6
32	The emerging role of peptidylâ€prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. Journal of Neurochemistry, 2015, 133, 1-13.	2.1	81
33	Souvenaid for Alzheimer's disease. The Cochrane Library, 2015, , .	1.5	2
34	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metabolism Reviews, 2015, 47, 470-519.	1.5	58
35	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. Molecular Neurodegeneration, 2015, 10, 68.	4.4	69
36	Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Neuroscience, 2015, 290, 530-542.	1.1	68

#	Article	IF	CITATIONS
37	Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 633-643.	1.8	81
38	Encapsulated Choroid Plexus Epithelial Cells Actively Protect Against Intrahippocampal AÎ ² -induced Long-Term Memory Dysfunction; Upregulation of Effective Neurogenesis with the Abrogated Apoptosis and Neuroinflammation. Journal of Molecular Neuroscience, 2015, 56, 708-721.	1.1	18
39	Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer's disease. Neurological Sciences, 2015, 36, 1181-1188.	0.9	44
40	Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2015, 24, 393-399.	1.9	64
41	Impact of nuclear factorâ€⊮B on restoration of neuron growth and differentiation in hippocampus of degenerative brain. Journal of Neuroscience Research, 2015, 93, 1471-1475.	1.3	9
42	Angiotensin and Neurovascular Coupling: Beyond Hypertension. Microcirculation, 2015, 22, 159-167.	1.0	28
43	Aβ "Stretching-and-Packing―Cross-Seeding Mechanism Can Trigger Tau Protein Aggregation. Journal of Physical Chemistry Letters, 2015, 6, 3276-3282.	2.1	42
44	BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer's Disease. International Journal of Molecular Sciences, 2015, 16, 2879-2892.	1.8	28
45	Modeling the complex pathology of Alzheimer's disease in Drosophila. Experimental Neurology, 2015, 274, 58-71.	2.0	54
46	Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5225-5230.	3.3	120
47	Liraglutide Promotes Cortical Neurite Outgrowth via the MEK–ERK Pathway. Cellular and Molecular Neurobiology, 2015, 35, 987-993.	1.7	19
48	Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease. SpringerPlus, 2015, 4, 25.	1.2	41
49	Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathologica, 2015, 130, 21-34.	3.9	234
50	Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2015, 35, 4857-4868.	1.7	122
51	Intracellular amyloid \hat{I}^2 oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathologica Communications, 2015, 3, 51.	2.4	52
52	Therapeutic Potential of <i>α</i> 7 Nicotinic Acetylcholine Receptors. Pharmacological Reviews, 2015, 67, 1025-1073.	7.1	123
53	Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice. Neuroscience Bulletin, 2015, 31, 491-504.	1.5	27
54	Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing AÎ ² Generation and Amyloid Plaque Pathogenesis. Journal of Neuroscience, 2015, 35, 12137-12151.	1.7	193

# 55	ARTICLE The Melatonin– <i>N</i> , <i>N</i> -Dibenzyl(<i>N</i> -methyl)amine Hybrid ITH91/IQM157 Affords Neuroprotection in an in Vitro Alzheimer's Model via Hemo-oxygenase-1 Induction. ACS Chemical Neuroscience, 2015, 6, 288-296.	IF 1.7	Citations 27
56	Tau aggregation and its interplay with amyloid- \hat{l}^2 . Acta Neuropathologica, 2015, 129, 207-220.	3.9	283
57	Connecting the dots between tau dysfunction and neurodegeneration. Trends in Cell Biology, 2015, 25, 46-53.	3.6	108
58	Mitochondrial Biology and Neurological Diseases. Current Neuropharmacology, 2016, 14, 143-154.	1.4	96
59	The mTOR Signaling Pathway in Neurodegenerative Diseases. , 2016, , 85-104.		3
60	Emerging Roles for the Immune System in Traumatic Brain Injury. Frontiers in Immunology, 2016, 7, 556.	2.2	198
61	Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. Frontiers in Neurology, 2016, 7, 55.	1.1	131
62	Tau: The Center of a Signaling Nexus in Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 31.	1.4	94
63	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. Korean Journal of Radiology, 2016, 17, 827.	1.5	61
64	Physical Exercise and Brain Mitochondrial Fitness: The Possible Role Against <scp>A</scp> lzheimer's Disease. Brain Pathology, 2016, 26, 648-663.	2.1	73
65	Intramuscular delivery of p75 <scp>NTR</scp> ectodomain by an <scp>AAV</scp> vector attenuates cognitive deficits and Alzheimer's diseaseâ€ike pathologies in APP/ <scp>PS</scp> 1 transgenic mice. Journal of Neurochemistry, 2016, 138, 163-173.	2.1	29
66	Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation. Journal of Alzheimer's Disease, 2016, 51, 1057-1068.	1.2	22
67	HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. Journal of Neuroinflammation, 2016, 13, 194.	3.1	145
68	From Common to Rare Variants: The Genetic Component of Alzheimer Disease. Human Heredity, 2016, 81, 129-141.	0.4	37
69	Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 934-939.	1.7	89
70	Alzheimer disease: modeling an Aβ-centered biological network. Molecular Psychiatry, 2016, 21, 861-871.	4.1	47
71	Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2016, 65, 326-340.	2.9	58
72	Neurochemical Aspects of Alzheimer Disease. , 2016, , 1-76.		1

#	Article	IF	CITATIONS
73	Nanotopography promoted neuronal differentiation of human induced pluripotent stem cells. Colloids and Surfaces B: Biointerfaces, 2016, 148, 49-58.	2.5	111
74	Potential mechanisms and implications for the formation of tau oligomeric strains. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 482-496.	2.3	64
75	Application of Nanomedicine to the CNS Diseases. International Review of Neurobiology, 2016, 130, 73-113.	0.9	17
76	Electroconvulsive therapy selectively enhances amyloid β 1–42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology, 2016, 26, 1877-1884.	0.3	20
77	Untangling Neurons With Endothelial Nitric Oxide. Circulation Research, 2016, 119, 1052-1054.	2.0	17
78	Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer's Research and Therapy, 2016, 8, 47.	3.0	12
79	SIRT1 as a therapeutic target for Alzheimer's disease. Reviews in the Neurosciences, 2016, 27, 813-825.	1.4	41
80	Neuroimaging Advances in Alzheimer's Disease. , 2016, , 263-282.		1
81	Drug treatments in Alzheimer's disease. Clinical Medicine, 2016, 16, 247-253.	0.8	344
82	Mathematical model on Alzheimer's disease. BMC Systems Biology, 2016, 10, 108.	3.0	86
83	Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. OMICS A Journal of Integrative Biology, 2016, 20, 645-661.	1.0	122
84	Alzheimer's disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Scientific Reports, 2016, 6, 28912.	1.6	37
85	Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathologica, 2016, 132, 875-895.	3.9	105
86	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 22.	3.0	39
87	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. Journal of Alzheimer's Disease, 2016, 53, 535-546.	1.2	4
88	Wnt / ß-Catenin Signaling Pathway Against Aβ Toxicity in PC12 Cells. NeuroSignals, 2016, 24, 40-47.	0.5	14
89	Mitochondria as a Target for Safety and Toxicity Evaluation of Nutraceuticals. , 2016, , 387-400.		2
90	Hybrid catechin silica nanoparticle influence on Cu(II) toxicity and morphological lesions in primary neuronal cells. Journal of Inorganic Biochemistry, 2016, 163, 240-249.	1.5	15

	CHAID	N REPORT	
#	Article	IF	Citations
91	Alzheimer's disease research in Ibero America. Alzheimer's and Dementia, 2016, 12, 749-754.	0.4	7
92	Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues. Molecular Brain, 2016, 9, 20.	1.3	30
93	Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis – What do we need to know?. Frontiers in Neuroendocrinology, 2016, 41, 153-171.	2.5	102
94	Practical Pharmacology for Alzheimer's Disease. , 2016, , .		2
95	Novel nanoparticulate drug delivery systems. Nanomedicine, 2016, 11, 573-576.	1.7	2
96	Lipoprotein binding to anionic biopolyelectrolytes and the effect of glucose on nanoplaque formation in arteriosclerosis and Alzheimer's disease. Advances in Colloid and Interface Science, 2016, 232, 25-35.	7.0	4
97	Circadian Rhythms, Sleep, and Disorders of Aging. Trends in Endocrinology and Metabolism, 2016, 27, 192-203.	3.1	247
98	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 34-39.	1.7	60
99	The Role of Proteases in Hippocampal Synaptic Plasticity: Putting Together Small Pieces of a Complex Puzzle. Neurochemical Research, 2016, 41, 156-182.	1.6	20
100	Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 2016, 53, 4833-4864.	1.9	52
101	Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures. Molecular Neurobiology, 2016, 53, 3338-3348.	1.9	23
102	Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase, 2016, 22, 76-83.	0.2	12
103	A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Al̂² Aggregation and Blocking the RAGE/Al̂² Axis. Molecular Neurobiology, 2017, 54, 1939-1952.	1.9	43
104	Small endogenous molecules as moiety to improve targeting of CNS drugs. Expert Opinion on Drug Delivery, 2017, 14, 93-107.	2.4	10
105	IL-5 blocks apoptosis and tau hyperphosphorylation induced by Aβ25–35 peptide in PC12 cells. Journal of Physiology and Biochemistry, 2017, 73, 259-266.	1.3	12
106	Aβ _{1–42} C-terminus fragment derived peptides prevent the self-assembly of the parent peptide. RSC Advances, 2017, 7, 4167-4173.	1.7	6
107	Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1910-1926.	2.4	51
108	Geniposide attenuates the level of Al̂²1–42 via enhancing leptin signaling in cellular and APP/PS1 transgenic mice. Archives of Pharmacal Research, 2017, 40, 571-578.	2.7	22

ARTICLE IF CITATIONS # Rho GTPase-activating proteins: Regulators of Rho GTPase activity in neuronal development and CNS 109 1.0 46 diseases. Molecular and Cellular Neurosciences, 2017, 80, 18-31. Immune Regulation of Antibody Access to Neuronal Tissues. Trends in Molecular Medicine, 2017, 23, 3.5 48 227-245. Impaired hypoxic tolerance in <scp>APP</scp>23 mice: a dysregulation of neuroprotective globin 111 7 1.3 levels. FEBS Letters, 2017, 591, 1321-1332. Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function. Journal of Pineal Research, 2017, 63, e12415. Emerging amyloid and tau targeting treatments for Alzheimer's disease. Expert Review of 113 1.4 11 Neurotherapeutics, 2017, 17, 697-711. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. Expert Review of 1.4 Neurotherapeutics, 2017, 17, 683-695. Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic 115 1.2 51 Compartment and Axonal Transport Dysfunction. Journal of Alzheimer's Disease, 2017, 58, 803-820. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony. Trends in Neurosciences, 2017, 4.2 327 40, 347-357. From the Cover: Comparative Proteomics Reveals Silver Nanoparticles Alter Fatty Acid Metabolism and 117 Amyloid Beta Clearance for Neuronal Apoptosis in a Triple Cell Coculture Model of the Bloodâ€"Brain 1.4 33 Barrier. Toxicological Sciences, 2017, 158, 151-163. 118 Spreading of Pathology in Alzheimer's Disease. Neurotoxicity Research, 2017, 32, 707-722. 1.3 Immune and myodegenerative pathomechanisms in inclusion body myositis. Annals of Clinical and 119 1.7 41 Translational Neurology, 2017, 4, 422-445. Current pharmacological developments in 2,3,4â€2,5-tetrahydroxystilbene 2-O-Î2-D-glucoside (TSG). 120 30 European Journal of Pharmacology, 2017, 811, 21-29. Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical 121 1.7 74 results. European Journal of Pharmacology, 2017, 817, 51-58. Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90. 1.5 Circadian Disruption Associated with Alzheimer's Disease. Current Neurology and Neuroscience 123 2.0 38 Reports, 2017, 17, 29. Roles of tau protein in health and disease. Acta Neuropathologica, 2017, 133, 665-704. 124 639 Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease. Ageing 125 5.038 Research Reviews, 2017, 36, 88-104. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Research Reviews, 2017, 36, 50-63.

#	Article	IF	CITATIONS
127	Impact of enriched environment on production of tau, amyloid precursor protein and, amyloid-β peptide in high-fat and high-sucrose-fed rats. Acta Neuropsychiatrica, 2017, 29, 291-298.	1.0	17
128	Major Depression as a Neuroprogressive Prelude to Dementia: What Is the Evidence?. Modern Problems of Pharmacopsychiatry, 2017, 31, 56-66.	2.5	24
129	Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer's disease pathology. Scientific Reports, 2017, 7, 14189.	1.6	67
130	Human TAUP301L overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. Scientific Reports, 2017, 7, 12959.	1.6	29
131	Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift. Neuron, 2017, 95, 1246-1265.	3.8	518
132	Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fynâ€mediated local protein translation. EMBO Journal, 2017, 36, 3120-3138.	3.5	140
133	Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 2017, 38, 1205-1235.	2.8	1,094
134	Resolution of inflammation, n â ^{~,} 3 fatty acid supplementation and Alzheimer disease: A narrative review. Journal of Neuroimmunology, 2017, 310, 111-119.	1.1	17
135	Matrix Metalloproteinases, Neural Extracellular Matrix, and Central Nervous System Pathology. Progress in Molecular Biology and Translational Science, 2017, 148, 167-202.	0.9	30
136	Autophagy, mitophagy and apoptotic gene changes in the hippocampal CA1 area in a rat ischemic model of Alzheimer's disease. Pharmacological Reports, 2017, 69, 1289-1294.	1.5	47
137	Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. Cell Stem Cell, 2017, 21, 319-331.e8.	5.2	254
138	Hippocampal synaptic and neural network deficits in young mice carrying the human <i><scp>APOE</scp>4</i> gene. CNS Neuroscience and Therapeutics, 2017, 23, 748-758.	1.9	32
139	A peptide-based near-infrared fluorescence probe for dynamic monitoring senile plaques in Alzheimer's disease mouse model. Science Bulletin, 2017, 62, 1593-1601.	4.3	10
140	Extracellular Vesicles in Neurodegenerative Diseases: A Double-Edged Sword. Tissue Engineering and Regenerative Medicine, 2017, 14, 667-678.	1.6	34
141	Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis?. Journal of Alzheimer's Disease, 2017, 60, 1097-1106.	1.2	14
142	Neuroimaging in the Diagnosis of Chronic Traumatic Encephalopathy: A Systematic Review. Clinical Journal of Sport Medicine, 2020, 30, S1-S10.	0.9	21
143	A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets. Scientific Reports, 2017, 7, 4983.	1.6	13
144	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2017, 58, 747-762.	1.2	9

#	Article	IF	CITATIONS
145	Regulator of Cell Cycle (RGCC) Expression during the Progression of Alzheimer's Disease. Cell Transplantation, 2017, 26, 693-702.	1.2	41
146	Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Annals of Anatomy, 2017, 209, 51-60.	1.0	14
147	Plasma amyloid beta peptides: an Alzheimer's conundrum or a more accessible Alzheimer's biomarker?. Expert Review of Neurotherapeutics, 2017, 17, 3-5.	1.4	9
148	mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 152-167.	0.4	65
149	Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases, 2017, 8, 139-163.	0.7	100
150	The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy. Neurobiology of Aging, 2017, 49, 40-51.	1.5	30
151	¹⁸ F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain, 2017, 140, aww340.	3.7	174
152	An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1079-1096.	1.2	15
153	Failure to Recover from Proactive Semantic Interference and Abnormal Limbic Connectivity in Asymptomatic, Middle-Aged Offspring of Patients with Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1183-1193.	1.2	31
154	PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67
155	Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice. Oncotarget, 2017, 8, 27676-27692.	0.8	45
156	Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases. Current Medicinal Chemistry, 2017, 24, 4245-4266.	1.2	60
157	Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases. International Journal of Molecular Sciences, 2017, 18, 2633.	1.8	39
158	Contribution of Nucleic Acids in the Pathogenesis of Alzheimer's Disease. , 2017, , 129-162.		0
159	Perspective, Summary, and Directions for Future Research on Alzheimer's Disease. , 2017, , 361-386.		0
160	Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models. International Journal of Molecular Sciences, 2017, 18, 2504.	1.8	106
161	The GABA–Working Memory Relationship in Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2017, 1, 43-45.	1.2	15
162	Rebalancing β-Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β-Protein Fragment 25-35. International Journal of Molecular Sciences, 2017, 18, 2154.	1.8	26

ARTICLE IF CITATIONS Biotechnological and Pharmacological Applications of Biotoxins and Other Bioactive Molecules from 2.2 63 163 Dinoflagellates. Marine Drugs, 2017, 15, 393. Vitamin C, Aging and Alzheimer's Disease. Nutrients, 2017, 9, 670. 164 1.7 Treatment Mechanisms in Mild to Moderate Alzheimer's Disease. , 2017, , 89-149. 0 165 Amyloid Î² Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. , 2017, , 109-143. Novel Treatment Strategies Using TiO2-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease. 167 0.9 23 International Review of Neurobiology, 2017, 137, 123-165. The Intersection of NGF/TrkA Signaling and Amyloid Precursor Protein Processing in Alzheimer's Disease Neuropathology. International Journal of Molecular Sciences, 2017, 18, 1319. 1.8 56 PGC-11± or FNDC5 Is Involved in Modulating the Effects of Al²1a²42 Oligomers on Suppressing the Expression of BDNF, a Beneficial Factor for Inhibiting Neuronal Apoptosis, Al² Deposition and Cognitive 169 1.7 45 Decline of APP/PS1 Tg Mice. Frontiers in Aging Neuroscience, 2017, 9, 65. Perspective Insights of Exosomes in Neurodegenerative Diseases: A Critical Appraisal. Frontiers in 1.7 79 Aging Neuroscience, 2017, 9, 317. Low Serum Phosphorus Correlates with Cerebral A² Deposition in Cognitively Impaired Subjects: 171 1.7 14 Results from the KBASE Study. Frontiers in Aging Neuroscience, 2017, 9, 362. Enhanced Feedback-Related Negativity in Alzheimer's Disease. Frontiers in Human Neuroscience, 2017, 11, 1.0 179. Human Excretion of Polybrominated Diphenyl Ether Flame Retardants: Blood, Urine, and Sweat Study. 173 31 0.9 BioMed Research International, 2017, 2017, 1-14. Alzheimer's amyloid-β A2T variant and its N-terminal peptides inhibit amyloid-β fibrillization and rescue 174 1.1 24 the induced cytotoxicity. PLoS ONE, 2017, 12, e0174561 Neurochemical Aspects of Î²-Amyloid Cascade Hypothesis for Alzheimer's Disease. , 2017, , 1-46. 175 0 Liposomal Drug Delivery to the Central Nervous System., 0, , . mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain 177 1.1 56 Research, 2018, 1693, 75-91. Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an 178 mTOR-Independent Pathway. ACS Chemical Neuroscience, 2018, 9, 1366-1379. Joint associations of \hat{l}^2 -amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 179 1.527 65, 121-131. Functional and structural connectome properties in the 5XFAD transgenic mouse model of 1.4 Alzheimer's disease. Network Neuroscience, 2018, 2, 241-258.

#	Article	IF	CITATIONS
181	Brain alphaâ€amylase: a novel energy regulator important in Alzheimer disease?. Brain Pathology, 2018, 28, 920-932.	2.1	33
182	SLAB51 Probiotic Formulation Activates SIRT1 Pathway Promoting Antioxidant and Neuroprotective Effects in an AD Mouse Model. Molecular Neurobiology, 2018, 55, 7987-8000.	1.9	172
183	Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. Npj Vaccines, 2018, 3, 9.	2.9	45
184	Subthreshold Amyloid Predicts Tau Deposition in Aging. Journal of Neuroscience, 2018, 38, 4482-4489.	1.7	101
185	Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimer's and Dementia, 2018, 14, 998-1004.	0.4	105
186	ROCK inhibition in models of neurodegeneration and its potential for clinical translation. , 2018, 189, 1-21.		136
187	Integrating in vitro and in silico approaches to evaluate the "dual functionality―of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1565-1575.	1.1	27
188	Endogenous Murine Amyloid-β Peptide Assembles into Aggregates in the Aged C57BL/6J Mouse Suggesting These Animals as a Model to Study Pathogenesis of Amyloid-β Plaque Formation. Journal of Alzheimer's Disease, 2018, 61, 1425-1450.	1.2	26
189	How the formation of amyloid plaques and neurofibrillary tangles may be related: a mathematical modelling study. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2018, 474, 20170777.	1.0	18
190	Advancements of the <scp>sFIDA</scp> method for oligomerâ€based diagnostics of neurodegenerative diseases. FEBS Letters, 2018, 592, 516-534.	1.3	10
191	Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents. ACS Chemical Neuroscience, 2018, 9, 1074-1094.	1.7	47
192	Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease. Current Opinion in Pharmacology, 2018, 38, 1-7.	1.7	29
193	<i>Caenorhabditis elegans</i> : A Convenient In Vivo Model for Assessing the Impact of Food Bioactive Compounds on Obesity, Aging, and Alzheimer's Disease. Annual Review of Food Science and Technology, 2018, 9, 1-22.	5.1	101
194	Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids. Scientific Reports, 2018, 8, 71.	1.6	41
195	Tau Proteins and Tauopathies in Alzheimer's Disease. Cellular and Molecular Neurobiology, 2018, 38, 965-980.	1.7	166
196	The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease. Progress in Neurobiology, 2018, 168, 104-127.	2.8	74
197	Proteasome stress leads to APP axonal transport defects by promoting its amyloidogenic processing in lysosomes. Journal of Cell Science, 2018, 131, .	1.2	8
198	Integrating Sleep and Alzheimer's Disease Pathophysiology: Hints for Sleep Disorders Management. Journal of Alzheimer's Disease, 2018, 63, 871-886.	1.2	20

#	Article	IF	CITATIONS
199	Longitudinal accrual of neocortical amyloid burden is associated with microstructural changes of the fornix in cognitively normal adults. Neurobiology of Aging, 2018, 68, 114-122.	1.5	29
200	VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacological Research, 2018, 131, 87-101.	3.1	153
201	Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. Journal of Alzheimer's Disease, 2018, 64, S517-S527.	1.2	42
202	Effects and mechanism of amyloid β1-42 on mitochondria in astrocytes. Molecular Medicine Reports, 2018, 17, 6997-7004.	1.1	17
203	Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
204	The potential inhibitory effect of β-casein on the aggregation and deposition of Aβ ₁₋₄₂ fibrils in Alzheimer's disease: insight from <i>invitro</i> and <i>insilico</i> studies. Journal of Biomolecular Structure and Dynamics, 2018, 36, 2118-2130.	2.0	9
205	Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1403-1416.	1.2	500
206	Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis. Neuropharmacology, 2018, 136, 192-195.	2.0	31
207	Early Alzheimer-type lesions in cognitively normal subjects. Neurobiology of Aging, 2018, 62, 34-44.	1.5	36
208	Derivation of Cortical Spheroids from Human Induced Pluripotent Stem Cells in a Suspension Bioreactor. Tissue Engineering - Part A, 2018, 24, 418-431.	1.6	35
209	Gene regulation of mammalian long non-coding RNA. Molecular Genetics and Genomics, 2018, 293, 1-15.	1.0	123
210	Tau Derived Hexapeptide AcPHF6 Promotes Beta-Amyloid (Aβ) Fibrillogenesis. ACS Chemical Neuroscience, 2018, 9, 773-782.	1.7	15
211	Protein phosphatase 2A and tau: an orchestrated â€~Pas de Deux'. FEBS Letters, 2018, 592, 1079-1095.	1.3	48
212	The Blood brain-barrier and its role in Alzheimer's disease. Neuroforum, 2018, 24, A197-A205.	0.2	13
213	Die Blut-Hirn-Schranke und ihre Rolle in der Alzheimer– Krankheit. Neuroforum, 2018, 24, 287-296.	0.2	0
214	Simulating the effect of formation of amyloid plaques on aggregation of tau protein. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2018, 474, 20180511.	1.0	18
215	Probiotics for Preventing Cognitive Impairment in Alzheimerâ \in ${}^{\mathrm{Ms}}$ s Disease. , 0, , .		9
216	Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease. Brain, 2018, 141, 2711-2720.	3.7	64

#	Article	IF	CITATIONS
217	Possible Clues for Brain Energy Translation via Endolysosomal Trafficking of APP-CTFs in Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	8
218	A Novel hAPP/htau Mouse Model of Alzheimer's Disease: Inclusion of APP With Tau Exacerbates Behavioral Deficits and Zinc Administration Heightens Tangle Pathology. Frontiers in Aging Neuroscience, 2018, 10, 382.	1.7	23
219	Ellagic acid ameliorates learning and memory impairment in APP/PS1 transgenic mice via inhibition of βa€'amyloid production and tau hyperphosphorylation. Experimental and Therapeutic Medicine, 2018, 16, 4951-4958.	0.8	21
220	Alzheimer's Disease:Intracellular Beta Amyloid Completes the Irreversible Pathway from Spirochetes to Biofilms to Beta Amyloid to Hyperphosphorylated Tau Protein. Journal of Neuroinfectious Diseases, 2018, 09, .	0.2	1
221	Deep Profiling of the Aggregated Proteome in Alzheimer's Disease: From Pathology to Disease Mechanisms. Proteomes, 2018, 6, 46.	1.7	23
222	Hippocampale synaptische Plastizitäbei neurodegenerativen Erkrankungen: Aβ, Tau und darüber hinaus. Neuroforum, 2018, 24, 203-212.	0.2	1
223	The Effect of Beta-Amyloid Peptides and Main Stress Protein HSP70 on Human SH-SY5Y Neuroblastoma Proteome. Molecular Biology, 2018, 52, 937-946.	0.4	0
224	TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism. Frontiers in Aging Neuroscience, 2018, 10, 395.	1.7	64
225	The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2018, 19, 3824.	1.8	244
226	Excitotoxicity. , 2018, , 70-100.		0
227	Positive Feedback Loops in Alzheimer's Disease: The Alzheimer's Feedback Hypothesis. Journal of Alzheimer's Disease, 2018, 66, 25-36.	1.2	32
228	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sciences, 2018, 8, 177.	1.1	139
229	Next-generation biomarker discovery in Alzheimer's disease using metabolomics – from animal to human studies. Bioanalysis, 2018, 10, 1525-1546.	0.6	27
230	Tau Protein Souired by Molecular Chaperones During Alzheimer's Disease. Iournal of Molecular		40
	Neuroscience, 2018, 66, 356-368.	1.1	49
231	Neuroscience, 2018, 66, 356-368. Filamentous Aggregates of Tau Proteins Fulfil Standard Amyloid Criteria Provided by the Fuzzy Oil Drop (FOD) Model. International Journal of Molecular Sciences, 2018, 19, 2910.	1.1	19
231 232	Neuroscience, 2018, 66, 356-368. Filamentous Aggregates of Tau Proteins Fulfil Standard Amyloid Criteria Provided by the Fuzzy Oil Drop (FOD) Model. International Journal of Molecular Sciences, 2018, 19, 2910. Hippocampal synaptic plasticity in neurodegenerative diseases: Aß, tau and beyond. Neuroforum, 2018, 24, A133-A141.	1.1 1.8 0.2	19 1
231 232 233	Neuroscience, 2018, 66, 356-368. Filamentous Aggregates of Tau Proteins Fulfil Standard Amyloid Criteria Provided by the Fuzzy Oil Drop (FOD) Model. International Journal of Molecular Sciences, 2018, 19, 2910. Hippocampal synaptic plasticity in neurodegenerative diseases: Aß, tau and beyond. Neuroforum, 2018, 24, A133-A141. Alzheimer's disease as a metabolic disorder. OCL - Oilseeds and Fats, Crops and Lipids, 2018, 25, D403.	1.1 1.8 0.2 0.6	49 19 1

#	Article	IF	CITATIONS
235	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy, 2018, 10, 107.	3.0	80
236	A novel lysosomeâ€ŧoâ€mitochondria signaling pathway disrupted by amyloidâ€Î² oligomers. EMBO Journal, 2018, 37, .	3.5	47
237	Ambiguous Effects of Autophagy Activation Following Hypoperfusion/Ischemia. International Journal of Molecular Sciences, 2018, 19, 2756.	1.8	31
238	Levels of Thyroid Hormones and Indices of Energy Metabolism in the Cerebral Cortex of Rats with Experimental Alzheimer's Disease. Neurophysiology, 2018, 50, 159-165.	0.2	5
239	Periodontal Pathogens and Associated Intrathecal Antibodies in Early Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 105-114.	1.2	43
240	Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration. Frontiers in Molecular Neuroscience, 2018, 11, 276.	1.4	61
241	Intracellular distribution of new tacrine analogues as a potential cause of their cytotoxicity against human neuroblastoma cells SH-SY5Y. Medicinal Chemistry Research, 2018, 27, 2353-2365.	1.1	3
242	Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimer's disease. BMC Medical Genomics, 2018, 11, 76.	0.7	12
243	A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease. Brain Sciences, 2018, 8, 162.	1.1	8
244	Caffeine: A Potential Protective Agent Against Cognitive Decline in Alzheimer's Disease. Critical Reviews in Eukaryotic Gene Expression, 2018, 28, 67-72.	0.4	9
245	Salivary biomarkers for the diagnosis andÂmonitoring of neurological diseases. Biomedical Journal, 2018, 41, 63-87.	1.4	122
246	Neurocognitive outcomes after aneurysmal subarachnoid hemorrhage: Identifying inflammatory biomarkers. Journal of the Neurological Sciences, 2018, 394, 84-93.	0.3	10
247	A Friend or Foe: Calcineurin across the Gamut of Neurological Disorders. ACS Central Science, 2018, 4, 805-819.	5.3	35
248	Clinical periodontal variables in patients with and without dementia—a systematic review and meta-analysis. Clinical Oral Investigations, 2018, 22, 2463-2474.	1.4	32
249	Disorder at the Tips of a Disease-Relevant Aβ42 Amyloid Fibril: A Molecular Dynamics Study. Journal of Physical Chemistry B, 2018, 122, 11072-11082.	1.2	24
250	Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. RSC Advances, 2018, 8, 23780-23804.	1.7	105
251	Influence of Zeolites on Amyloid-Î ² Aggregation. Langmuir, 2018, 34, 9789-9797.	1.6	14
252	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	3.0	21

#	Article	IF	CITATIONS
253	Targeting Renin–Angiotensin System Against Alzheimer's Disease. Frontiers in Pharmacology, 2018, 9, 440.	1.6	81
254	Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. Journal of Alzheimer's Disease, 2018, 63, 115-130.	1.2	10
255	In Vitro Anti-Cholinesterase and Antioxidant Activity of Extracts of Moringa oleifera Plants from Rivers State, Niger Delta, Nigeria. Medicines (Basel, Switzerland), 2018, 5, 71.	0.7	25
256	The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E584-E596.	1.8	10
257	Neuronal Cell Death. Physiological Reviews, 2018, 98, 813-880.	13.1	737
258	Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons. Journal of Alzheimer's Disease, 2018, 65, 409-419.	1.2	16
259	The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. Frontiers in Medicine, 2018, 5, 61.	1.2	589
260	Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus. Frontiers in Aging Neuroscience, 2018, 9, 434.	1.7	20
261	U1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease. Frontiers in Aging Neuroscience, 2018, 10, 75.	1.7	16
262	Autophagy in Age-Associated Neurodegeneration. Cells, 2018, 7, 37.	1.8	87
263	Nâ€methylâ€Dâ€aspartate receptor–mediated calcium influx connects amyloidâ€Î² oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1302-1312.	0.4	63
264	Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the Aβ42-Treated Forebrain Spheroids Derived from Human Stem Cells. ACS Biomaterials Science and Engineering, 2018, 4, 2922-2933.	2.6	25
265	Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2018, 63, 1089-1107.	1.2	20
266	MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathologica, 2018, 136, 537-555.	3.9	120
267	A Study of Amyloid-β and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2018, 64, 417-435.	1.2	54
268	Metal Ion Effects on AÎ ² and Tau Aggregation. International Journal of Molecular Sciences, 2018, 19, 128.	1.8	118
269	MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2018, 19, 1800.	1.8	32
270	Targeting Cellular Stress Mechanisms and Metabolic Homeostasis by Chinese Herbal Drugs for Neuroprotection. Molecules, 2018, 23, 259.	1.7	6

#	Article	IF	CITATIONS
271	In vitro neuroprotective effects of naringenin nanoemulsion against β-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation. International Journal of Biological Macromolecules, 2018, 118, 1211-1219.	3.6	86
272	Preventive Effects of Dairy Products on Dementia and the Underlying Mechanisms. International Journal of Molecular Sciences, 2018, 19, 1927.	1.8	43
273	Sirtuin 1 and Alzheimer's disease: An up-to-date review. Neuropeptides, 2018, 71, 54-60.	0.9	65
274	Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?. Pharmacological Research, 2018, 135, 37-48.	3.1	24
275	Hetero-oligomeric Amyloid Assembly and Mechanism: Prion Fragment PrP(106–126) Catalyzes the Islet Amyloid Polypeptide β-Hairpin. Journal of the American Chemical Society, 2018, 140, 9685-9695.	6.6	28
276	Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. Acta Neuropathologica, 2018, 136, 589-605.	3.9	29
277	Recent advancements toward therapeutic vaccines against Alzheimer's disease. Expert Review of Vaccines, 2018, 17, 707-721.	2.0	46
278	Contribution of Diabetes and Metabolic Syndrome in the Pathogenesis of Alzheimer's Disease. , 2018, , 301-316.		1
279	Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications. Frontiers in Aging Neuroscience, 2018, 10, 04.	1.7	285
280	Impacts of Acute Hypoxia on Alzheimer's Disease-Like Pathologies in APPswe/PS1dE9 Mice and Their Wild Type Littermates. Frontiers in Neuroscience, 2018, 12, 314.	1.4	25
281	Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy. Molecular Neurodegeneration, 2018, 13, 13.	4.4	60
282	Berberine: Pathways to protect neurons. Phytotherapy Research, 2018, 32, 1501-1510.	2.8	66
283	Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease. CNS Drugs, 2018, 32, 579-591.	2.7	4
284	Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model. Alzheimer's Research and Therapy, 2018, 10, 10.	3.0	23
285	Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons. Frontiers in Neuroscience, 2018, 12, 504.	1.4	39
286	Traumatic Brain Injury, Chronic Traumatic Encephalopathy, and Alzheimer Disease. Clinics in Geriatric Medicine, 2018, 34, 617-635.	1.0	20
287	Protein phosphatase 2A as therapeutic targets in various disease models. Life Sciences, 2018, 210, 40-46.	2.0	48
288	The Glymphatic System: A Review. Brazilian Neurosurgery, 2018, 37, 190-195.	0.0	3

#	Article	IF	CITATIONS
289	Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease. Drug Delivery, 2018, 25, 1091-1102.	2.5	147
290	Environmental Enrichment Improves Cognitive Deficits, AD Hallmarks and Epigenetic Alterations Presented in 5xFAD Mouse Model. Frontiers in Cellular Neuroscience, 2018, 12, 224.	1.8	70
291	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology, 2018, 157, 67-84.	2.0	75
292	Importance of GPCR-Mediated Microglial Activation in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 258.	1.8	31
293	The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	1.2	572
294	Chronic cerebral hypoperfusion accelerates Alzheimer's disease pathology with the change of mitochondrial fission and fusion proteins expression in a novel mouse model. Brain Research, 2018, 1696, 63-70.	1.1	18
295	Sirtuins as Modifiers of Huntington's Disease (HD) Pathology. Progress in Molecular Biology and Translational Science, 2018, 154, 105-145.	0.9	17
296	Development of an Effective Alzheimer's Vaccine. , 2018, , 149-169.		2
297	Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies. ACS Chemical Neuroscience, 2018, 9, 2731-2740.	1.7	16
298	Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer. Biochemistry and Cell Biology, 2019, 97, 158-164.	0.9	25
299	Targeting Neuroplasticity, Cardiovascular, and Cognitive-Associated Genomic Variants in Familial Alzheimer's Disease. Molecular Neurobiology, 2019, 56, 3235-3243.	1.9	7
300	The Future of Psychoneuroimmunology: Promises and Challenges. , 2019, , 235-266.		4
301	CDK5 Participates in Amyloid-β Production by Regulating PPARγ Phosphorylation in Primary Rat Hippocampal Neurons. Journal of Alzheimer's Disease, 2019, 71, 443-460.	1.2	12
302	Pioglitazone Reduces β Amyloid Levels via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 178.	1.7	28
303	Twendee X Ameliorates Phosphorylated Tau, α-Synuclein and Neurovascular Dysfunction in Alzheimer's Disease Transgenic Mice With Chronic Cerebral Hypoperfusion. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104310.	0.7	17
304	Unilateral Focused Ultrasound-Induced Blood-Brain Barrier Opening Reduces Phosphorylated Tau from The rTg4510 Mouse Model. Theranostics, 2019, 9, 5396-5411.	4.6	63
305	Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model. Journal of Alzheimer's Disease, 2019, 71, 327-339.	1.2	10
306	Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease. Frontiers in Computational Neuroscience, 2019, 13, 54.	1.2	83

#	Article	IF	CITATIONS
307	Liver Dysfunction as a Novel Player in Alzheimer's Progression: Looking Outside the Brain. Frontiers in Aging Neuroscience, 2019, 11, 174.	1.7	93
308	Extended multimodal whole-brain anatomical covariance analysis: detection of disrupted correlation networks related to amyloid deposition. Heliyon, 2019, 5, e02074.	1.4	4
309	Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells. Molecules, 2019, 24, 2687.	1.7	52
310	The cellular and molecular processes associated with scopolamine-induced memory deficit: A model of Alzheimer's biomarkers. Life Sciences, 2019, 233, 116695.	2.0	97
311	Ginsenoside compound K ameliorates Alzheimer's disease in HT22 cells by adjusting energy metabolism. Molecular Biology Reports, 2019, 46, 5323-5332.	1.0	12
312	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101954.	1.4	42
313	Structure and Physicochemical Properties of the Aî²42 Tetramer: Multiscale Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2019, 123, 7253-7269.	1.2	25
314	Antagonistic Activity of Naphthoquinone-Based Hybrids toward Amyloids Associated with Alzheimer's Disease and Type-2 Diabetes. ACS Chemical Neuroscience, 2019, 10, 3510-3520.	1.7	25
315	Cortisol, Amyloid-β, and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2019, 70, 553-562.	1.2	20
316	Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alzheimer's Research and Therapy, 2019, 11, 86.	3.0	59
317	A longitudinal assessment of retinal function and structure in the APP/PS1 transgenic mouse model of Alzheimer's disease. Translational Neurodegeneration, 2019, 8, 30.	3.6	30
318	Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer's disease. Progress in Neurobiology, 2019, 183, 101690.	2.8	20
319	Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility. International Journal of Molecular Sciences, 2019, 20, 5203.	1.8	92
320	Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses. Expert Review of Proteomics, 2019, 16, 951-964.	1.3	9
321	Dysregulation of Autophagy, Mitophagy, and Apoptosis Genes in the CA3 Region of the Hippocampus in the Ischemic Model of Alzheimer's Disease in the Rat. Journal of Alzheimer's Disease, 2019, 72, 1279-1286.	1.2	31
322	Inflammatory and Pro-resolving Mediators in Frontotemporal Dementia and Alzheimer's Disease. Neuroscience, 2019, 421, 123-135.	1.1	17
323	Loss in efficacy measures of tolfenamic acid in a tau knock-out model: Relevance to Alzheimer's disease. Experimental Biology and Medicine, 2019, 244, 1062-1069.	1.1	3
324	Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an APOE4 mouse model. PLoS ONE, 2019, 14, e0221828.	1.1	78

		CITATION	Report	
#	Article		IF	CITATIONS
325	Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 2019), 15, 565-581.	4.9	1,578
326	Application of T1-/T2-Weighted Ratio Mapping to Elucidate Intracortical Demyelination Alzheimer's Disease Continuum. Frontiers in Neuroscience, 2019, 13, 904.	Process in the	1.4	23
327	Rise and Fall of the Empire: Conquering Alzheimer's Disease by Targeting Adult Neu Currents, 2019, 19, 411-413.	urogenesis. Epilepsy	0.4	1
328	Intraneuronal Tau Misfolding Induced by Extracellular Amyloid-Î ² Oligomers. Journal of Disease, 2019, 71, 1125-1138.	Alzheimer's	1.2	18
329	Coffee, Caffeine and Cognition: a Benefit or Disadvantage?. Letters in Drug Design and 16, 1146-1156.	Discovery, 2019,	0.4	1
330	M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and mer by i-Extract from Withania somnifera. Scientific Reports, 2019, 9, 13990.	nory recovery	1.6	32
331	The United Chemicals of Cannabis: Beneficial Effects of Cannabis Phytochemicals on th Cognition. , 0, , .	ie Brain and		6
332	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's D Alzheimer's Disease, 2019, 72, S145-S176.	isease. Journal of	1.2	26
333	Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alz Disease. Journal of Alzheimer's Disease Reports, 2019, 3, 77-94.	heimer's	1.2	4
334	Apolipoprotein E4 Mediates the Association Between Midlife Dyslipidemia and Cerebra Aging Women. Journal of Alzheimer's Disease, 2019, 68, 105-114.	l Amyloid in	1.2	4
335	Investigating sensitivity coefficients characterizing the response of a model of tau prot in an axon to model parameters. Computer Methods in Biomechanics and Biomedical E 22, 71-83.	ein transport Engineering, 2019,	0.9	25
336	Testing the Neuroprotective Properties of PCSO-524® Using a Neuronal Cell Cycle Su Marine Drugs, 2019, 17, 79.	ppression Assay.	2.2	5
337	Aging, lifestyle and dementia. Neurobiology of Disease, 2019, 130, 104481.		2.1	97
338	Tau immunotherapies for Alzheimer's disease. Expert Opinion on Investigational Di 545-554.	rugs, 2019, 28,	1.9	55
339	Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and ap Neurobiology of Disease, 2019, 130, 104503.	plications.	2.1	24
340	Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Vitro Studies. Inorganic Chemistry, 2019, 58, 13509-13527.	Obtained from in	1.9	61
341	Deficits in Enrichment-Dependent Neurogenesis and Enhanced Anxiety Behaviors Medi Expression of Alzheimer's Disease-Linked Ps1 Variants Are Rescued by Microglial Deple Neuroscience, 2019, 39, 6766-6780.	ated by tion. Journal of	1.7	22
342	Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outo Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 201	comes in 19, 5, 1456.	3.4	77

#	Article	IF	Citations
343	18F-labeled benzimidazopyridine derivatives for PET imaging of tau pathology in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2019, 27, 3587-3594.	1.4	9
344	Alteration of scaffold: Possible role of MACF1 in Alzheimer's disease pathogenesis. Medical Hypotheses, 2019, 130, 109259.	0.8	4
345	Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review. European Journal of Pharmacology, 2019, 856, 172415.	1.7	64
346	In Vitro Neuronal Networks. Advances in Neurobiology, 2019, , .	1.3	12
347	Aerobic Exercise Improves Synaptic-Related Proteins of Diabetic Rats by Inhibiting FOXO1/NF-ήB/NLRP3 Inflammatory Signaling Pathway and Ameliorating PI3K/Akt Insulin Signaling Pathway. Journal of Molecular Neuroscience, 2019, 69, 28-38.	1.1	24
348	The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. Frontiers in Neuroendocrinology, 2019, 54, 100764.	2.5	79
349	In Vitro Models of Brain Disorders. Advances in Neurobiology, 2019, 22, 19-49.	1.3	3
350	How stress mediators can cumulatively contribute to Alzheimer's disease An allostatic load approach. Dementia E Neuropsychologia, 2019, 13, 11-21.	0.3	21
351	Effect of N-Acetyl Cysteine on Intracerebroventricular Colchicine Induced Cognitive Deficits, Beta Amyloid Pathology, and Glial Cells. Neuroscience Journal, 2019, 2019, 1-15.	2.3	7
352	Neurochemical Aspects of Alzheimer's Type of Dementia. , 2019, , 73-112.		1
353	Proteomic Profiles of the Early Mitochondrial Changes in APP/PS1 and ApoE4 Transgenic Mice Models of Alzheimer's Disease. Journal of Proteome Research, 2019, 18, 2632-2642.	1.8	18
354	Using a portable total reflection Xâ€ray fluorescence system for a multielement analysis of Swiss mice brains with experimental Alzheimer's disease induced by βâ€amyloid oligomers. X-Ray Spectrometry, 2019, 48, 452-464.	0.9	4
355	Adenoâ€associated virusâ€based Alzheimer's disease mouse models and potential new therapeutic avenues. British Journal of Pharmacology, 2019, 176, 3649-3665.	2.7	22
356	Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathologica Communications, 2019, 7, 26.	2.4	25
357	iPSCs-derived nerve-like cells from familial Alzheimer's disease PSEN 1 E280A reveal increased amyloid-beta levels and loss of the Y chromosome. Neuroscience Letters, 2019, 703, 111-118.	1.0	11
358	Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Neurotrauma, 2019, 36, 2549-2557.	1.7	10
359	Docosahexaenoic Acid Increases the Potency of Soluble Epoxide Hydrolase Inhibitor in Alleviating Streptozotocin-Induced Alzheimer's Disease-Like Complications of Diabetes. Frontiers in Pharmacology, 2019, 10, 288.	1.6	20
360	Orengedokuto and san'oshashinto improve memory deficits by inhibiting aging-dependent activation of glycogen synthase kinase-31². Journal of Traditional and Complementary Medicine, 2019, 9, 328-335.	1.5	6

#	Article	IF	CITATIONS
361	Interval timing is disrupted in female 5xFAD mice: An indication of altered memory processes. Journal of Neuroscience Research, 2019, 97, 817-827.	1.3	16
362	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. Neuropharmacology, 2019, 151, 21-32.	2.0	7
363	Copper-Induced Upregulation of MicroRNAs Directs the Suppression of Endothelial LRP1 in Alzheimer's Disease Model. Toxicological Sciences, 2019, 170, 144-156.	1.4	23
364	The potential of memory enhancement through modulation of perineuronal nets. British Journal of Pharmacology, 2019, 176, 3611-3621.	2.7	27
365	Transition Metal Ion Interactions with Disordered Amyloid-β Peptides in the Pathogenesis of Alzheimer's Disease: Insights from Computational Chemistry Studies. Journal of Chemical Information and Modeling, 2019, 59, 1782-1805.	2.5	46
366	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
367	Dysfunctional Mitochondrial Bioenergetics and Synaptic Degeneration in Alzheimer Disease. International Neurourology Journal, 2019, 23, S5-10.	0.5	50
368	Cognition and Health Ageing. , 2019, , 169-180.		1
369	The New Application of UHPLC-DAD-TOF/MS in Identification of Inhibitors on β-Amyloid Fibrillation From Scutellaria baicalensis. Frontiers in Pharmacology, 2019, 10, 194.	1.6	16
370	Cortico-hippocampal memory enhancing activity of hesperetin on scopolamine-induced amnesia in mice: role of antioxidant defense system, cholinergic neurotransmission and expression of BDNF. Metabolic Brain Disease, 2019, 34, 979-989.	1.4	25
371	Collagen Based Multicomponent Interpenetrating Networks as Promising Scaffolds for 3D Culture of Human Neural Stem Cells, Human Astrocytes, and Human Microglia. ACS Applied Bio Materials, 2019, 2, 975-980.	2.3	14
372	Fungal Metabolites as Promising New Drug Leads for the Treatment of Alzheimer's Disease. Studies in Natural Products Chemistry, 2019, , 1-39.	0.8	4
373	â€~Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro. Journal of Alzheimer's Disease Reports, 2019, 3, 19-29.	1.2	4
374	Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine, 2019, 61, 152842.	2.3	23
375	Higher Apolipoprotein C-III Levels in Cerebrospinal Fluid are Associated with Slower Cognitive Decline in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 961-969.	1.2	6
376	Resveratrol Abrogates Hypoxia-Induced Up-Regulation of Exosomal Amyloid-β Partially by Inhibiting CD147. Neurochemical Research, 2019, 44, 1113-1126.	1.6	16
377	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.5	194
378	Amyloid β Induces Early Changes in the Ribosomal Machinery, Cytoskeletal Organization and Oxidative Phosphorylation in Retinal Photoreceptor Cells. Frontiers in Molecular Neuroscience, 2019, 12, 24.	1.4	28

		CITATION R	EPORT	
#	Article		IF	Citations
379	The Role of NMDA Receptors in Alzheimer's Disease. Frontiers in Neuroscience, 20	19, 13, 43.	1.4	275
380	Novel model of secreted human tau protein reveals the impact of the abnormal N-glyco on its aggregation propensity. Scientific Reports, 2019, 9, 2254.	osylation of tau	1.6	26
381	The Role of Apolipoprotein E Isoforms in Alzheimer's Disease. Journal of Alzheimer' 459-471.	s Disease, 2019, 68,	1.2	21
382	31 Alzheimer's Disease: Epidemiology, Pathophysiology and Surgery. , 2019, , .			0
383	Current state of research on nonâ€human primate models of Alzheimer's disease. Experimental Medicine, 2019, 2, 227-238.	Animal Models and	1.3	29
384	Family C C-Protein-Coupled Receptors in Alzheimer's Disease and Therapeutic Impl Pharmacology, 2019, 10, 1282.	ications. Frontiers in	1.6	20
385	Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hip Patients With Alzheimer's Disease. Frontiers in Neuroanatomy, 2019, 13, 99.	pocampus of	0.9	32
386	Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimer's di Medicinal Chemistry, 2019, 11, 3161-3178.	sease. Future	1.1	25
387	Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregate Function, 2019, 10, 7865-7874.	es. Food and	2.1	21
388	Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimerâ€ Molecular Brain, 2019, 12, 104.	™s disease.	1.3	172
389	Therapeutic Potential of AAV1-Rheb(S16H) Transduction Against Alzheimer's Disea Clinical Medicine, 2019, 8, 2053.	ase. Journal of	1.0	5
391	HHV-6A infection induces amyloid-beta expression and activation of microglial cells. Al Research and Therapy, 2019, 11, 104.	zheimer's	3.0	48
392	Different Amyloid-β Self-Assemblies Have Distinct Effects on Intracellular Tau Aggrega in Molecular Neuroscience, 2019, 12, 268.	tion. Frontiers	1.4	13
394	CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer Parkinson's disease and spasticity. Neuropharmacology, 2019, 147, 4-10.	's disease,	2.0	17
395	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyle Neurobiology of Aging, 2019, 73, 61-67.	oid pathology.	1.5	75
396	Genetic and epigenetic regulation of human aging and longevity. Biochimica Et Biophy Molecular Basis of Disease, 2019, 1865, 1718-1744.	sica Acta -	1.8	84
397	Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr20 interneurons and its modulation by Tau mutations (VLW) and amyloid-Î ² peptide. Neur Disease, 2019, 125, 232-244.)5 in hippocampal obiology of	2.1	17
398	It's all about tau. Progress in Neurobiology, 2019, 175, 54-76.		2.8	134

#	Article	IF	CITATIONS
399	Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease. Drug Discovery Today, 2019, 24, 616-623.	3.2	43
400	Apolipoprotein D Upregulation in Alzheimer's Disease but Not Frontotemporal Dementia. Journal of Molecular Neuroscience, 2019, 67, 125-132.	1.1	29
402	The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel. Molecular Neurobiology, 2019, 56, 5416-5435.	1.9	53
403	Molecular Pathogenesis of the Tauopathies. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 239-261.	9.6	161
404	Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer's compounds: In vitro and in vivo biological evaluation and docking study. Bioorganic Chemistry, 2019, 83, 303-316.	2.0	94
405	Neuroprotection and improvement of the histopathological and behavioral impairments in a murine Alzheimer's model treated with Zephyranthes carinata alkaloids. Biomedicine and Pharmacotherapy, 2019, 110, 482-492.	2.5	12
406	Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 852-862.	1.7	88
407	Identifying Brain Connectivity Using Network-Based Statistics in Amnestic Mild Cognitive Impairment Stratified by β-Amyloid Positivity. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 104-111.	0.9	8
408	Circadian Rhythms and Disease. , 2019, , 299-314.		5
409	Sex differences in the timing behavior performance of 3xTg-AD and wild-type mice in the peak interval procedure. Behavioural Brain Research, 2019, 360, 235-243.	1.2	21
410	Changes in cortical protein markers of iron transport with gender, major depressive disorder and suicide. World Journal of Biological Psychiatry, 2020, 21, 119-126.	1.3	12
411	Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. CNS Spectrums, 2020, 25, 402-408.	0.7	14
412	Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system. Pharmacological Research, 2020, 154, 104230.	3.1	37
413	Rationale for the development of an Alzheimer's disease vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 645-653.	1.4	16
414	The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models. Neurobiology of Aging, 2020, 86, 39-53.	1.5	25
415	Classification of Alzheimer's disease based on brain MRI and machine learning. Neural Computing and Applications, 2020, 32, 1927-1936.	3.2	41
416	Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model. Cellular and Molecular Life Sciences, 2020, 77, 2795-2813.	2.4	46
417	Biomarkers and brains: situating dementia in the laboratory and in the memory clinic. New Genetics and Society, 2020, 39, 80-100.	0.7	0

#	Article	IF	CITATIONS
418	Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease. Brain Pathology, 2020, 30, 319-331.	2.1	31
419	Experimental alcoholism primes structural and functional impairment of the glymphatic pathway. Brain, Behavior, and Immunity, 2020, 85, 106-119.	2.0	13
420	WALTZ-DB 2.0: an updated database containing structural information of experimentally determined amyloid-forming peptides. Nucleic Acids Research, 2020, 48, D389-D393.	6.5	64
421	Neuropathologic basis of in vivo cortical atrophy in the aphasic variant of Alzheimer's disease. Brain Pathology, 2020, 30, 332-344.	2.1	11
422	Exercise enhances the effectiveness of vitamin D therapy in rats with Alzheimer's disease: emphasis on oxidative stress and inflammation. Metabolic Brain Disease, 2020, 35, 111-120.	1.4	25
423	Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice. Journal of Neuroscience, 2020, 40, 1581-1593.	1.7	40
424	Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. Neuron, 2020, 105, 975-991.e7.	3.8	287
425	O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease. NeuroMolecular Medicine, 2020, 22, 171-193.	1.8	32
426	Ultrasonic waves effect on S-shaped β-amyloids conformational dynamics by non-equilibrium molecular dynamics. Journal of Molecular Graphics and Modelling, 2020, 96, 107518.	1.3	8
427	Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy. Progress in Neurobiology, 2020, 186, 101743.	2.8	26
428	Amyloid Peptide Scaffolds Coordinate with Alzheimer's Disease Drugs. Journal of Physical Chemistry B, 2020, 124, 487-503.	1.2	5
429	Reduction in the neuronal surface of post and presynaptic GABA _B receptors in the hippocampus in a mouse model of Alzheimer's disease. Brain Pathology, 2020, 30, 554-575.	2.1	22
430	Environmental lead exposure aggravates the progression of Alzheimer's disease in mice by targeting on blood brain barrier. Toxicology Letters, 2020, 319, 138-147.	0.4	33
431	Gut microbiota manipulation through probiotics oral administration restores glucose homeostasis in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2020, 87, 35-43.	1.5	77
432	Picrorhiza kurroa Prevents Memory Deficits by Inhibiting NLRP3 Inflammasome Activation and BACE1 Expression in 5xFAD Mice. Neurotherapeutics, 2020, 17, 189-199.	2.1	30
433	Advances and considerations in AD tau-targeted immunotherapy. Neurobiology of Disease, 2020, 134, 104707.	2.1	70
434	1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 187, 111916.	2.6	33
435	Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer's Disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 211-226.	2.5	39

#	Article	IF	CITATIONS
436	MiR-107 overexpression attenuates neurotoxicity induced by 6-hydroxydopamine both in vitro and in vivo. Chemico-Biological Interactions, 2020, 315, 108908.	1.7	18
437	Transition metal nickel prevents Tau aggregation in Alzheimer's disease. International Journal of Biological Macromolecules, 2020, 156, 1359-1365.	3.6	15
438	Oxidative stress in alzheimer's disease: A review on emergent natural polyphenolic therapeutics. Complementary Therapies in Medicine, 2020, 49, 102294.	1.3	151
439	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	3.0	33
440	Effects of U1 Small Nuclear Ribonucleoprotein Inhibition on the Expression of Genes Involved in Alzheimer's Disease. ACS Omega, 2020, 5, 25306-25311.	1.6	1
441	β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	3.0	16
442	Local Sleep and Alzheimer's Disease Pathophysiology. Frontiers in Neuroscience, 2020, 14, 525970.	1.4	50
443	Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer's Disease. Frontiers in Pharmacology, 2020, 11, 584770.	1.6	24
444	Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer's disease therapy. Science Advances, 2020, 6, .	4.7	135
445	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 40.	4.4	438
446	Extracellular Vesicles of Alzheimer's Disease Patients as a Biomarker for Disease Progression. Molecular Neurobiology, 2020, 57, 4156-4169.	1.9	40
447	Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
449	TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease. Nature Communications, 2020, 11, 5950.	5.8	45
450	Phytohormone Abscisic Acid Improves Memory Impairment and Reduces Neuroinflammation in 5xFAD Mice by Upregulation of LanC-Like Protein 2. International Journal of Molecular Sciences, 2020, 21, 8425.	1.8	14
451	Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 9036.	1.8	30
452	Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques. Molecular Neurodegeneration, 2020, 15, 66.	4.4	22
453	Neuron Loss in Alzheimer's Disease: Translation in Transgenic Mouse Models. International Journal of Molecular Sciences, 2020, 21, 8144.	1.8	39
454	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Journal of Nuclear Medicine, 2020, 61, 1413-1418.	2.8	17

#	Article	IF	CITATIONS
455	Role of tau protein in Alzheimer's disease: The prime pathological player. International Journal of Biological Macromolecules, 2020, 163, 1599-1617.	3.6	100
456	Plasma BDNF Levels Following Transcranial Direct Current Stimulation Allow Prediction of Synaptic Plasticity and Memory Deficits in 3×Tg-AD Mice. Frontiers in Cell and Developmental Biology, 2020, 8, 541.	1.8	16
457	Slow Wave Sleep Is a Promising Intervention Target for Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 705.	1.4	55
458	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 63.	1.1	13
459	The Role of BMI1 in Late-Onset Sporadic Alzheimer's Disease. Genes, 2020, 11, 825.	1.0	7
460	Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. Ageing Research Reviews, 2020, 62, 101130.	5.0	22
461	<i>In silico</i> exploration of the fingerprints triggering modulation of glutaminyl cyclase inhibition for the treatment of Alzheimer's disease using SMILES based attributes in Monte Carlo optimization. Journal of Biomolecular Structure and Dynamics, 2021, 39, 7181-7193.	2.0	10
462	The proteostatic effects of traffic-derived air pollution on Alzheimer's disease risk. Open Biology, 2020, 10, 200146.	1.5	2
463	Age-Dependent Shift of AMPA Receptors From Synapses to Intracellular Compartments in Alzheimer's Disease: Immunocytochemical Analysis of the CA1 Hippocampal Region in APP/PS1 Transgenic Mouse Model. Frontiers in Aging Neuroscience, 2020, 12, 577996.	1.7	18
464	Axonal Degeneration in AD: The Contribution of Al ² and Tau. Frontiers in Aging Neuroscience, 2020, 12, 581767.	1.7	28
465	On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications. Frontiers in Immunology, 2020, 11, 571083.	2.2	22
466	Effect of Moxibustion on Behavioral Changes and Expression of APP and BACE1 in Hippocampus of SAMP8 Mice. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	2
467	Alzheimer's Disease Progressively Alters the Face-Evoked Visual-Processing Network. Journal of Alzheimer's Disease, 2020, 77, 1025-1042.	1.2	11
468	Functions of p38 MAP Kinases in the Central Nervous System. Frontiers in Molecular Neuroscience, 2020, 13, 570586.	1.4	80
469	Dietary Pattern, Diet Quality, and Dementia: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Journal of Alzheimer's Disease, 2020, 78, 151-168.	1.2	38
470	Electroacupuncture at GV24 and bilateral GB13 improves cognitive ability via influences the levels of Aβ, p-tau (s396) and p-tau (s404) in the hippocampus of Alzheimer's disease model rats. NeuroReport, 2020, 31, 1072-1083.	0.6	14
471	Circuitry and Synaptic Dysfunction in Alzheimer's Disease: A New Tau Hypothesis. Neural Plasticity, 2020, 2020, 1-11.	1.0	19
472	The Retinal Inner Plexiform Synaptic Layer Mirrors Grey Matter Thickness of Primary Visual Cortex with Increased Amyloid <i>β</i> Load in Early Alzheimer's Disease. Neural Plasticity, 2020, 2020, 1-11.	1.0	13

#	Article	IF	CITATIONS
473	Dimethyl Fumarate Mitigates Tauopathy in AÎ ² -Induced Neuroblastoma SH-SY5Y Cells. Neurochemical Research, 2020, 45, 2641-2652.	1.6	11
474	Emerging Roles of Tripartite Motif-Containing Family Proteins (TRIMs) in Eliminating Misfolded Proteins. Frontiers in Cell and Developmental Biology, 2020, 8, 802.	1.8	20
475	Structural conversion of human islet amyloid polypeptide aggregates under an electric field. Chemical Communications, 2020, 56, 11497-11500.	2.2	2
476	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	1.0	74
477	Alzheimer's disease: natural products as inhibitors of neuroinflammation. Inflammopharmacology, 2020, 28, 1439-1455.	1.9	43
478	Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	1.8	79
479	Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. Journal of Neuroinflammation, 2020, 17, 374.	3.1	28
480	Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer's Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging. Frontiers in Aging Neuroscience, 2020, 12, 550664.	1.7	14
481	Natural Compounds as Inhibitors of AÎ ² Peptide Aggregation: Chemical Requirements and Molecular Mechanisms. Frontiers in Neuroscience, 2020, 14, 619667.	1.4	59
482	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679.	1.5	4
482 483	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071.	1.5 1.7	4
482 483 484	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143.	1.5 1.7 3.3	4 17 24
482 483 484 485	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143. The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46.	1.5 1.7 3.3 0.5	4 17 24 6
482 483 484 485 486	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143. The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46. Inflammation in Traumatic Brain Injury. Journal of Alzheimer's Disease, 2020, 74, 1-28.	1.5 1.7 3.3 0.5 1.2	4 17 24 6 36
482 483 484 485 485 486	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143. The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46. Inflammation in Traumatic Brain Injury. Journal of Alzheimer's Disease, 2020, 74, 1-28. Mechanisms of neurodegeneration â€" Insights from familial Alzheimer's disease. Seminars in Cell and Developmental Biology, 2020, 105, 75-85.	1.5 1.7 3.3 0.5 1.2 2.3	4 17 24 6 36 35
482 483 484 485 485 486 487	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143. The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46. Inflammation in Traumatic Brain Injury. Journal of Alzheimer's Disease, 2020, 74, 1-28. Mechanisms of neurodegeneration â€" Insights from familial Alzheimer's disease. Seminars in Cell and Developmental Biology, 2020, 105, 75-85. Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice. Journal of Neuroscience, 2020, 40, 4596-4608.	1.5 1.7 3.3 0.5 1.2 2.3 1.7	4 17 24 6 36 35 35
 482 483 484 485 485 486 487 488 489 	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679. Does Diet Have a Role in the Treatment of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2020, 12, 617071. The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143. The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46. Inflammation in Traumatic Brain Injury. Journal of Alzheimer's Disease, 2020, 74, 1-28. Mechanisms of neurodegeneration — Insights from familial Alzheimer's disease. Seminars in Cell and Developmental Biology, 2020, 105, 75-85. Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Senstivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice. Journal of Neuroscience, 2020, 40, 4596-4608. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimer's Research and Therapy, 2020, 12, 55.	1.5 1.7 3.3 0.5 1.2 2.3 1.7 3.0	 4 17 24 6 36 35 4 21

#	Article	IF	CITATIONS
491	The potential roles of deubiquitinating enzymes in brain diseases. Ageing Research Reviews, 2020, 61, 101088.	5.0	37
492	Mitochondrial Dysfunction: a Potential Therapeutic Target to Treat Alzheimer's Disease. Molecular Neurobiology, 2020, 57, 3075-3088.	1.9	68
493	Insulin resistance and Alzheimer's disease. , 2020, , 249-292.		1
495	The relationship between the brain and spirituality with respect to aging and neurodegenerative diseases: clinical and research implications. Journal of Religion, Spirituality and Aging, 2020, 32, 357-380.	0.5	0
496	Selective neuronal vulnerability in Alzheimer's disease. Ageing Research Reviews, 2020, 62, 101114.	5.0	9
497	Prognostic value of ATN Alzheimer biomarkers: 60â€month followâ€up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12026.	1.2	20
498	1,25(OH)2D3 Alleviates Al̂²(25-35)-Induced Tau Hyperphosphorylation, Excessive Reactive Oxygen Species, and Apoptosis Through Interplay with Glial Cell Line-Derived Neurotrophic Factor Signaling in SH-SY5Y Cells. International Journal of Molecular Sciences, 2020, 21, 4215.	1.8	25
499	Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease. Journal of Pharmacological Sciences, 2020, 143, 290-299.	1.1	37
500	Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimer's disease. Metabolic Brain Disease, 2020, 35, 681-693.	1.4	20
501	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. ACS Medicinal Chemistry Letters, 2020, 11, 1973-1979.	1.3	12
502	Prion protein codon 129 polymorphism in mild cognitive impairment and dementia: the Rotterdam Study. Brain Communications, 2020, 2, fcaa030.	1.5	3
503	Acetylation of $A\hat{I}^2$ 42 at Lysine 16 Disrupts Amyloid Formation. ACS Chemical Neuroscience, 2020, 11, 1178-1191.	1.7	18
504	Peroxisomal Dysfunction in Neurological Diseases and Brain Aging. Frontiers in Cellular Neuroscience, 2020, 14, 44.	1.8	29
505	Neuropathological Mechanisms Associated with Pesticides in Alzheimer's Disease. Toxics, 2020, 8, 21.	1.6	40
506	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
507	MAP/ERK Signaling in Developing Cognitive and Emotional Function and Its Effect on Pathological and Neurodegenerative Processes. International Journal of Molecular Sciences, 2020, 21, 4471.	1.8	96
508	Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database. Journal of the Neurological Sciences, 2020, 416, 116989.	0.3	18
509	Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis. Expert Opinion on Therapeutic Targets, 2020, 24, 859-868.	1.5	11

#	Article	IF	CITATIONS
510	TREM2 ectodomain and its soluble form in Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 204.	3.1	55
511	Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA–Protein Interaction. ACS Chemical Neuroscience, 2020, 11, 2277-2285.	1.7	17
512	Bidirectional Dysregulation of AMPA Receptor-Mediated Synaptic Transmission and Plasticity in Brain Disorders. Frontiers in Synaptic Neuroscience, 2020, 12, 26.	1.3	32
513	Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	1.4	56
514	Enhancing α-secretase Processing for Alzheimer's Disease—A View on SFRP1. Brain Sciences, 2020, 10, 122.	. 1.1	9
515	Chinese medicine Di-Huang-Yi-Zhi protects PC12 cells from H2O2-induced apoptosis by regulating ROS-ASK1-JNK/p38 MAPK signaling. BMC Complementary Medicine and Therapies, 2020, 20, 54.	1.2	3
516	Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease. Translational Psychiatry, 2020, 10, 47.	2.4	44
517	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies. Frontiers in Molecular Neuroscience, 2019, 12, 319.	1.4	15
518	Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 1327.	1.8	10
519	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiology of Disease, 2020, 139, 104811.	2.1	44
520	Spatial navigation ability predicts progression of dementia symptomatology. Alzheimer's and Dementia, 2020, 16, 491-500.	0.4	31
521	Safflower Yellow Improves Synaptic Plasticity in APP/PS1 Mice by Regulating Microglia Activation Phenotypes and BDNF/TrkB/ERK Signaling Pathway. NeuroMolecular Medicine, 2020, 22, 341-358.	1.8	23
522	OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages. EBioMedicine, 2020, 51, 102569.	2.7	10
523	Elucidating the Effect of Static Electric Field on Amyloid Beta 1–42 Supramolecular Assembly. Journal of Molecular Graphics and Modelling, 2020, 96, 107535.	1.3	14
524	Protein-based amide proton transfer-weighted MR imaging of amnestic mild cognitive impairment. NeuroImage: Clinical, 2020, 25, 102153.	1.4	19
525	Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence. Nutrients, 2020, 12, 259.	1.7	50
526	Association Between Atg5-independent Alternative Autophagy and Neurodegenerative Diseases. Journal of Molecular Biology, 2020, 432, 2622-2632.	2.0	17
527	Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 192-217.	2.0	69

#	Article	IF	CITATIONS
528	Intracerebral seeding of amyloid-β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with α-synuclein. Neuroscience and Biobehavioral Reviews, 2020, 112, 1-27.	2.9	31
529	Apolipoprotein E: Cholesterol metabolism and Alzheimer's pathology. Neuroforum, 2020, 26, 25-30.	0.2	0
530	d-ribose and pathogenesis of Alzheimer's disease. Molecular Biology Reports, 2020, 47, 2289-2299.	1.0	14
531	Galectin 3–binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein. Journal of Biological Chemistry, 2020, 295, 3678-3691.	1.6	29
532	Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains. Cell, 2020, 180, 633-644.e12.	13.5	300
533	Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models. Brain Communications, 2020, 2, fcaa039.	1.5	29
534	Exploring the multifaceted neuroprotective actions of gallic acid: a review. International Journal of Food Properties, 2020, 23, 736-752.	1.3	47
535	<i>N</i> -Amino peptide scanning reveals inhibitors of Aβ ₄₂ aggregation. RSC Advances, 2020, 10, 14331-14336.	1.7	8
536	Saliva in Health and Disease. , 2020, , .		15
537	Insulin resistance, diabetes, and metabolic syndrome. , 2020, , 71-112.		1
538	Functional roles of circular RNAs in Alzheimer's disease. Ageing Research Reviews, 2020, 60, 101058.	5.0	31
539	Anatomy and function of the fornix in the context of its potential as a therapeutic target. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 547-559.	0.9	58
540	Serum tau levels are increased in patients with hyperthyroidism. Neuroscience Letters, 2020, 729, 135003.	1.0	5
541	Circadian and sleep dysfunction in Alzheimer's disease. Ageing Research Reviews, 2020, 60, 101046.	5.0	99
542	The multi-faceted impact of methamphetamine on Alzheimer's disease: From a triggering role to a possible therapeutic use. Ageing Research Reviews, 2020, 60, 101062.	5.0	26
543	p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators. Journal of Medicinal Chemistry, 2020, 63, 10135-10157.	2.9	26
544	Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges. Expert Opinion on Drug Discovery, 2020, 15, 803-822.	2.5	37
545	Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury. Cell Communication and Signaling, 2020, 18, 62.	2.7	111

#	Article	IF	CITATIONS
546	Inflammatory Responses in the Secondary Thalamic Injury After Cortical Ischemic Stroke. Frontiers in Neurology, 2020, 11, 236.	1.1	22
547	Density of GABAB Receptors Is Reduced in Granule Cells of the Hippocampus in a Mouse Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 2459.	1.8	21
548	Biomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clÃnica de memoria de Latinoamérica. NeurologÃa, 2021, 36, 201-208.	0.3	5
549	Fucosterol from <i>Sargassum horridum</i> as an amyloid-beta (Aβ ₁₋₄₂) aggregation inhibitor: <i>inÂvitro</i> and <i>in silico</i> studies. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1271-1283.	2.0	16
550	Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Research Reviews, 2021, 65, 101208.	5.0	160
551	D-Glucose uptake and clearance in the tauopathy Alzheimer's disease mouse brain detected by on-resonance variable delay multiple pulse MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1013-1025.	2.4	27
552	A White Matter Connection of Schizophrenia and Alzheimer's Disease. Schizophrenia Bulletin, 2021, 47, 197-206.	2.3	35
553	Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. International Journal of Neuropsychopharmacology, 2021, 24, 142-157.	1.0	8
554	Amelioration of oxidative stress and neuroinflammation in lipopolysaccharide-induced memory impairment using Rosmarinic acid in mice. Metabolic Brain Disease, 2021, 36, 299-313.	1.4	26
555	Mitochondrial dysfunction in the development and progression of neurodegenerative diseases. Archives of Biochemistry and Biophysics, 2021, 702, 108698.	1.4	126
556	Frontiers in Neuroscience Imaging. PET Clinics, 2021, 16, 137-146.	1.5	1
557	Morphine and HIV-1 Tat interact to cause region-specific hyperphosphorylation of tau in transgenic mice. Neuroscience Letters, 2021, 741, 135502.	1.0	14
558	Role of Ten eleven translocation $\hat{a} \in 2$ (Tet2) in modulating neuronal morphology and cognition in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 2021, 157, 993-1012.	2.1	17
559	Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations. NeuroImage, 2021, 227, 117646.	2.1	10
560	Inhibitory Effects of Isobavachalcone on Tau Protein Aggregation, Tau Phosphorylation, and Oligomeric Tau-Induced Apoptosis. ACS Chemical Neuroscience, 2021, 12, 123-132.	1.7	17
561	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	1.6	34
562	Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease. FEBS Journal, 2021, 288, 2836-2855.	2.2	60
563	Early Mitochondrial Fragmentation and Dysfunction in a Drosophila Model for Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 143-155.	1.9	16

#	Article	IF	CITATIONS
564	Differential effects of putative N-glycosylation sites in human Tau on Alzheimer's disease-related neurodegeneration. Cellular and Molecular Life Sciences, 2021, 78, 2231-2245.	2.4	28
565	Biomarkers of Alzheimer disease in mild cognitive impairment: Experience in a memory clinic from Latin America. NeurologÃa (English Edition), 2021, 36, 201-208.	0.2	0
566	Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures. Scientific Reports, 2021, 11, 621.	1.6	17
567	Dual targeting nano-approaches for Alzheimer's disease etiology. Neural Regeneration Research, 2021, 16, 119.	1.6	4
568	Amyloid Beta. , 2021, , 1-17.		0
569	The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis. Advances in Experimental Medicine and Biology, 2021, 1301, 41-57.	0.8	80
570	Axonal mRNA localization and local translation in neurodegenerative disease. Neural Regeneration Research, 2021, 16, 1950.	1.6	6
571	Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology. Frontiers in Neurology, 2020, 11, 607680.	1.1	17
572	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. Progress in Brain Research, 2021, 265, 139-230.	0.9	9
573	Calcium Signalling in Alzheimer's Disease: From Pathophysiological Regulation to Therapeutic Approaches. Cells, 2021, 10, 140.	1.8	6
574	Tacrine-sugar mimetic conjugates as enhanced cholinesterase inhibitors. Organic and Biomolecular Chemistry, 2021, 19, 2322-2337.	1.5	8
575	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid-β. Current Topics in Medicinal Chemistry, 2021, 21, 151-167.	1.0	5
576	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Progress in Brain Research, 2021, 265, 1-97.	0.9	8
577	Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease. Pharmaceuticals, 2021, 14, 95.	1.7	27
578	The biological pathways of Alzheimer disease: a review. AIMS Neuroscience, 2021, 8, 86-132.	1.0	111
580	A Westernâ€style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease—A populationâ€based crossâ€sectional study among 70â€yearâ€olds. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12183.	1.8	11
581	A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids. Nature Communications, 2021, 12, 280.	5.8	88
582	Does Impairment of Adult Neurogenesis Contribute to Pathophysiology of Alzheimer's Disease? A Still Open Question. Frontiers in Molecular Neuroscience, 2020, 13, 578211.	1.4	23

#	Article	IF	CITATIONS
583	Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus, 2021, 13, e12759.	0.2	41
584	Greenspace Inversely Associated with the Risk of Alzheimer's Disease in the Mid-Atlantic United States. Earth, 2021, 2, 140-150.	0.9	8
585	CD36 – A novel molecular target in the neurovascular unit. European Journal of Neuroscience, 2021, 53, 2500-2510.	1.2	17
586	The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease. Diagnostics, 2021, 11, 371.	1.3	24
587	Alzheimer's Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models. Biomolecules, 2021, 11, 262.	1.8	39
588	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	2.4	17
589	Effects of Alzheimer's and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 606600.	1.4	7
590	Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice. Journal of Alzheimer's Disease, 2021, 79, 1813-1829.	1.2	4
591	Catalytic Cross Talk between Key Peptide Fragments That Couple Alzheimer's Disease with Amyotrophic Lateral Sclerosis. Journal of the American Chemical Society, 2021, 143, 3494-3502.	6.6	10
592	Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. Alzheimer's Research and Therapy, 2021, 13, 40.	3.0	53
593	Body mass index trajectories and the risk for Alzheimer's disease among older adults. Scientific Reports, 2021, 11, 3087.	1.6	22
594	fISHing with immunohistochemistry for housekeeping gene changes in Alzheimer's disease using an automated quantitative analysis workflow. Journal of Neurochemistry, 2021, 157, 1270-1283.	2.1	5
595	The Impact of Disease Comorbidities in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 631770.	1.7	105
596	Amyloid-Î ² and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. European Journal of Medicinal Chemistry, 2021, 214, 113209.	2.6	33
597	Crosstalk among Calcium ATPases: PMCA, SERCA and SPCA in Mental Diseases. International Journal of Molecular Sciences, 2021, 22, 2785.	1.8	9
598	Alpiniae oxyphyllae Fructus and Alzheimer's disease: An update and current perspective on this traditional Chinese medicine. Biomedicine and Pharmacotherapy, 2021, 135, 111167.	2.5	32
600	Exploring new avenues for modifying course of progression of Alzheimer's disease: The rise of natural medicine. Journal of the Neurological Sciences, 2021, 422, 117332.	0.3	6
601	Increased Alu RNA processing in Alzheimer brains is linked to gene expression changes. EMBO Reports, 2021, 22, e52255.	2.0	12

	Сітатіої	n Report	
#	Article	IF	CITATIONS
602	N-methyl-d-aspartate receptor blockade reduces plasticity-related tau expression and phosphorylation of tau at Ser416 residue but not Thr231 residue. Experimental Brain Research, 2021, 239, 1627-1637.	0.7	3
603	The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer's Disease: Exploring Interactions With Sex. Frontiers in Neuroscience, 2021, 15, 633576.	1.4	7
605	TUFM is involved in Alzheimer's diseaseâ€like pathologies that are associated with ROS. FASEB Journal, 2021, 35, e21445.	0.2	10
606	Bifidobacterium Lactis Probio-M8 regulates gut microbiota to alleviate Alzheimer's disease in the APP/PS1 mouse model. European Journal of Nutrition, 2021, 60, 3757-3769.	1.8	37
607	Key Disease Mechanisms Linked to Alzheimer's Disease in the Entorhinal Cortex. International Journal of Molecular Sciences, 2021, 22, 3915.	1.8	17
608	Role of Hypoxia Inducible Factor-1α in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 949-961.	1.2	22
610	Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer's Disease. Journal of Clinical Medicine, 2021, 10, 1555.	1.0	9
611	Genome instability and loss of protein homeostasis: converging paths to neurodegeneration?. Open Biology, 2021, 11, 200296.	1.5	26
612	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. Frontiers in Neuroinformatics, 2021, 15, 630172.	1.3	20
613	Understanding Changes in Hippocampal Interneurons Subtypes in the Pathogenesis of Alzheimer's Disease: A Systematic Review. Brain Connectivity, 2021, 11, 159-179.	0.8	8
614	Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 405-411.	1.2	2
615	Physical Exercise-Induced Myokines in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 5795.	1.8	23
616	Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 4122-4133.	1.9	23
617	Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer's disease. Journal of Biosciences, 2021, 46, 1.	0.5	16
618	Effect of antiamyloid-β drugs on Alzheimer's disease: study protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e048453.	0.8	0
619	Diabetes, Albuminuria and the Kidney—Brain Axis. Journal of Clinical Medicine, 2021, 10, 2364.	1.0	9
620	Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways. Current Neuropharmacology, 2021, 19, 885-895.	1.4	6
621	Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands. International Journal of Biological Macromolecules, 2021, 178, 381-393.	3.6	27

#	Article	IF	CITATIONS
622	The Moringin/α-CD Pretreatment Induces Neuroprotection in an In Vitro Model of Alzheimer's Disease: A Transcriptomic Study. Current Issues in Molecular Biology, 2021, 43, 197-214.	1.0	13
623	Characterization of a Mouse Model of Alzheimer's Disease Expressing Aβ4-42 and Human Mutant Tau. International Journal of Molecular Sciences, 2021, 22, 5191.	1.8	7
624	Assessment of the Level of Rage in Cells Blood-Brain Barrier in Experimental Alzheimer's Disease. Cell and Tissue Biology, 2021, 15, 280-286.	0.2	2
625	Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. Critical Reviews in Food Science and Nutrition, 2022, 62, 7929-7959.	5.4	41
626	Hydrogen Sulfide Ameliorates Lipopolysaccharide-Induced Memory Impairment in Mice by Reducing Apoptosis, Oxidative, and Inflammatory Effects. Neurotoxicity Research, 2021, 39, 1310-1322.	1.3	14
627	The Impact of High Glucose or Insulin Exposure on S100B Protein Levels, Oxidative and Nitrosative Stress and DNA Damage in Neuron-Like Cells. International Journal of Molecular Sciences, 2021, 22, 5526.	1.8	6
628	Alzheimer's Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. Frontiers in Neuroscience, 2021, 15, 687973.	1.4	18
629	Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules, 2021, 11, 767.	1.8	39
630	Reduced coupling between cerebrospinal fluid flow and global brain activity is linked to Alzheimer disease–related pathology. PLoS Biology, 2021, 19, e3001233.	2.6	44
631	Amyloid-β: a potential link between epilepsy and cognitive decline. Nature Reviews Neurology, 2021, 17, 469-485.	4.9	60
632	Ren Shen Yang Rong Tang and other traditional Chinese medicines exhibit antioxidant and anti-inflammatory capacities and suppress acetylcholinesterase activity in PC12 neuronal cells. Longhua Chinese Medicine, 0, 4, 13-13.	0.5	0
633	NOX2 Activation in COVID-19: Possible Implications for Neurodegenerative Diseases. Medicina (Lithuania), 2021, 57, 604.	0.8	18
634	Multichromatic fluorescence towards aberrant proteinaceous aggregates utilizing benzimidazole-based ICT fluorophores. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2021, 101, 205-215.	0.9	8
635	Dietary intervention with edible medicinal plants and derived products for prevention of Alzheimer's disease: A compendium of time-tested strategy. Journal of Functional Foods, 2021, 81, 104463.	1.6	15
636	CK1δ-Derived Peptides as Novel Tools Inhibiting the Interactions between CK1δ and APP695 to Modulate the Pathogenic Metabolism of APP. International Journal of Molecular Sciences, 2021, 22, 6423.	1.8	1
637	The neural economics of brain aging. Scientific Reports, 2021, 11, 12167.	1.6	0
638	Nutraceutical and Probiotic Approaches to Examine Molecular Interactions of the Amyloid Precursor Protein APP in Drosophila Models of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7022.	1.8	5
639	Interactions of Amyloid- \hat{I}^2 with Membrane Proteins. International Journal of Molecular Sciences, 2021, 22, 6075.	1.8	19

#	Article	IF	CITATIONS
640	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
641	Sanweidoukou decoction, a Chinese herbal formula, ameliorates β-amyloid protein-induced neuronal insult via modulating MAPK/NF-βB signaling pathways: Studies in vivo and in vitro. Journal of Ethnopharmacology, 2021, 273, 114002.	2.0	12
642	Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 128016.	1.0	6
643	Lindera glauca Blume ameliorates amyloid-β1-42-induced memory impairment in mice with neuroprotection and activation of the CREB-BDNF pathway. Neurochemistry International, 2021, 147, 105071.	1.9	4
644	Association between dementia and hepatitis B and C virus infection. Medicine (United States), 2021, 100, e26476.	0.4	14
645	A network pharmacology approach to uncover the key ingredients in Ginkgo Folium and their anti-Alzheimer's disease mechanisms. Aging, 2021, 13, 18993-19012.	1.4	12
646	Computational Insights Into the Inhibition Mechanism of Proanthocyanidin B2 on Tau Hexapeptide (PHF6) Oligomer. Frontiers in Chemistry, 2021, 9, 666043.	1.8	6
647	Estrogen Deficiency Induces Mitochondrial Damage Prior to Emergence of Cognitive Deficits in a Postmenopausal Mouse Model. Frontiers in Aging Neuroscience, 2021, 13, 713819.	1.7	12
648	Neuronal αâ€amylase is important for neuronal activity and glycogenolysis and reduces in presence of amyloid beta pathology. Aging Cell, 2021, 20, e13433.	3.0	7
649	Disruption of the astrocyte–neuron interaction is responsible for the impairments in learning and memory in 5XFAD mice: an Alzheimer's disease animal model. Molecular Brain, 2021, 14, 111.	1.3	12
650	Alzheimer's Disease Progressively Reduces Visual Functional Network Connectivity. Journal of Alzheimer's Disease Reports, 2021, 5, 549-562.	1.2	17
651	Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies—A Non-Systematic Review. International Journal of Molecular Sciences, 2021, 22, 7366.	1.8	15
652	GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease. Seminars in Cell and Developmental Biology, 2021, 116, 146-159.	2.3	77
653	Increased oscillatory power in a computational model of the olfactory bulb due to synaptic degeneration. Physical Review E, 2021, 104, 024405.	0.8	1
654	Curiosity-Based Interventions Increase Everyday Functioning Score But Not Serum BDNF Levels in a Cohort of Healthy Older Adults. Frontiers in Aging, 2021, 2, .	1.2	0
655	Amyloid-β toxicity modulates tau phosphorylation through the PAX6 signalling pathway. Brain, 2021, 144, 2759-2770.	3.7	23
656	Recent Applications of Retro-Inverso Peptides. International Journal of Molecular Sciences, 2021, 22, 8677.	1.8	48
657	The role of P62 in the development of human thyroid cancer and its possible mechanism. Cancer Genetics, 2021, 256-257, 5-16.	0.2	3

#	Article	IF	CITATIONS
658	Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases. Current Neuropharmacology, 2021, 19, 1273-1303.	1.4	28
659	A γ-adducin cleavage fragment induces neurite deficits and synaptic dysfunction in Alzheimer's disease. Progress in Neurobiology, 2021, 203, 102074.	2.8	7
660	Neuroprotective Effects of Glochidion zeylanicum Leaf Extract against H2O2/Glutamate-Induced Toxicity in Cultured Neuronal Cells and Al²-Induced Toxicity in Caenorhabditis elegans. Biology, 2021, 10, 800.	1.3	7
661	The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Frontiers in Cell and Developmental Biology, 2021, 9, 683459.	1.8	94
663	Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. International Journal of Molecular Sciences, 2021, 22, 8769.	1.8	12
664	Elevated Plasma Free Fatty Acid Susceptible to Early Cognitive Impairment in Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2021, 82, 1345-1356.	1.2	3
665	Association Between Antibiotic Treatment of Chlamydia pneumoniae and Reduced Risk of Alzheimer Dementia: A Nationwide Cohort Study in Taiwan. Frontiers in Aging Neuroscience, 2021, 13, 701899.	1.7	7
666	Comparison of early F-18 Florbetaben PET/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis. Scientific Reports, 2021, 11, 16738.	1.6	4
667	Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166162.	1.8	20
668	Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?. Cells, 2021, 10, 1992.	1.8	18
669	The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
670	Long-Term Treatment of Cuban Policosanol Attenuates Abnormal Oxidative Stress and Inflammatory Response via Amyloid Plaques Reduction in 5xFAD Mice. Antioxidants, 2021, 10, 1321.	2.2	9
672	The Beneficial Role of Exercise on Treating Alzheimer's Disease by Inhibiting β-Amyloid Peptide. Molecular Neurobiology, 2021, 58, 5890-5906.	1.9	12
674	A Fluorine-19 Magnetic Resonance Probe, Shiga-Y5, Downregulates Thioredoxin-Interacting Protein Expression in the Brain of a Mouse Model of Alzheimer's Disease. Molecules, 2021, 26, 5342.	1.7	1
675	An intracerebroventricular injection of amyloid-beta peptide (1–42) aggregates modifies daily temporal organization of clock factors expression, protein carbonyls and antioxidant enzymes in the rat hippocampus. Brain Research, 2021, 1767, 147449.	1.1	5
676	Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer. Bioscience Reports, 2021, 41, .	1.1	4
677	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126779.	1.5	60
678	Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived Aspergillus niger. PLoS ONE, 2021, 16, e0257071.	1.1	10

#	Article	IF	CITATIONS
679	Ophthalmic Biomarkers for Alzheimer's Disease: A Review. Frontiers in Aging Neuroscience, 2021, 13, 720167.	1.7	15
680	Green Tea Polyphenol Epigallocatechin-Gallate in Amyloid Aggregation and Neurodegenerative Diseases. Frontiers in Neuroscience, 2021, 15, 718188.	1.4	39
681	Idebenone Decreases AÎ ² Pathology by Modulating RAGE/Caspase-3 Signaling and the AÎ ² Degradation Enzyme NEP in a Mouse Model of AD. Biology, 2021, 10, 938.	1.3	7
682	Neuroprotective potential of berberine in modulating Alzheimer's disease via multiple signaling pathways. Journal of Food Biochemistry, 2021, 45, e13936.	1.2	33
683	Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration. Current Molecular Pharmacology, 2022, 15, 361-379.	0.7	16
684	Glypican 4 Regulates AÎ ² Internalization in Neural Stem Cells Partly via Low-Density Lipoprotein Receptor-Related Protein 1. Frontiers in Cellular Neuroscience, 2021, 15, 732429.	1.8	4
685	Palmitoylated Prolactin-releasing Peptide Reduced AÎ ² Plaques and Microgliosis in the Cerebellum: APP/PS1 Mice Study. Current Alzheimer Research, 2021, 18, 607-622.	0.7	4
686	NAD ⁺ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS–STING. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	176
687	Synaptic tau: A pathological or physiological phenomenon?. Acta Neuropathologica Communications, 2021, 9, 149.	2.4	30
688	Retinal Vasculopathy in Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 731614.	1.4	40
690	Illuminating Protein Phase Separation: Reviewing Aggregationâ€Induced Emission, Fluorescent Molecular Rotor and Solvatochromic Fluorophore Based Probes. Chemistry - A European Journal, 2021, 27, 14564-14576.	1.7	12
691	Phenylalanine Metabolism Is Dysregulated in Human Hippocampus with Alzheimer's Disease Related Pathological Changes. Journal of Alzheimer's Disease, 2021, 83, 609-622.	1.2	24
692	Interactions of copper and copper chelate compounds with the amyloid beta peptide: An investigation into electrochemistry, reactive oxygen species and peptide aggregation. Journal of Inorganic Biochemistry, 2021, 222, 111493.	1.5	7
693	Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer's Disease. Metabolites, 2021, 11, 616.	1.3	16
694	Effects of All-Atom Molecular Mechanics Force Fields on Amyloid Peptide Assembly: The Case of PHF6 Peptide of Tau Protein. Journal of Chemical Theory and Computation, 2021, 17, 6458-6471.	2.3	23
695	The effect of the use of copper carbonate and copper nanoparticles in the diet of rats on the level of β-amyloid and acetylcholinesterase in selected organs. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126777.	1.5	6
696	NLRP3 Inflammasome-Dependent Increases in High Mobility Group Box 1 Involved in the Cognitive Dysfunction Caused by Tau-Overexpression. Frontiers in Aging Neuroscience, 2021, 13, 721474.	1.7	9
697	Formaldehydeâ€Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives. ChemMedChem, 2021, 16, 3376-3390.	1.6	12

#	Article	IF	CITATIONS
698	Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice. Journal of Alzheimer's Disease, 2021, 84, 671-690.	1.2	10
699	The Alzheimer–E. coli Axis: What Can We Learn from an Electronic Health Record Platform. Journal of Alzheimer's Disease, 2021, 84, 717-721.	1.2	2
700	Plasma extracellular vesicles tau and βâ€∎myloid as biomarkers of cognitive dysfunction of Parkinson's disease. FASEB Journal, 2021, 35, e21895.	0.2	23
701	Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease?. Analytical Biochemistry, 2022, 636, 114387.	1.1	12
702	Tau and MAPT genetics in tauopathies and synucleinopathies. Parkinsonism and Related Disorders, 2021, 90, 142-154.	1.1	26
703	Neuroprotective Effects of Palmatine via the Enhancement of Antioxidant Defense and Small Heat Shock Protein Expression in AÎ2-Transgenic Caenorhabditis elegans. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	16
704	Brain aging mechanisms with mechanical manifestations. Mechanisms of Ageing and Development, 2021, 200, 111575.	2.2	57
705	Fatty acids and beyond: Age and Alzheimer's disease related changes in lipids reveal the neuro-nutraceutical potential of lipids in cognition. Neurochemistry International, 2021, 149, 105143.	1.9	20
706	The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders. Pharmacological Research, 2021, 172, 105805.	3.1	23
707	Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease. Bioorganic Chemistry, 2021, 116, 105354.	2.0	13
708	Transplantation of gut microbiota derived from Alzheimer's disease mouse model impairs memory function and neurogenesis in C57BL/6 mice. Brain, Behavior, and Immunity, 2021, 98, 357-365.	2.0	93
709	Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting Aβ cascade pathogenesis. Journal of Chemical Neuroanatomy, 2021, 117, 102014.	1.0	22
710	GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25–35 in a rat model of Alzheimer's disease. Neuropeptides, 2021, 90, 102200.	0.9	23
711	Using big data methods to understand Alzheimer's disease. , 2022, , 125-149.		1
712	Mitochondria as a target for safety and toxicity evaluation of nutraceuticals. , 2021, , 463-483.		1
713	Neuroprotective Effects of Extracts from Tiger Milk Mushroom Lignosus rhinocerus Against Glutamate-Induced Toxicity in HT22 Hippocampal Neuronal Cells and Neurodegenerative Diseases in Caenorhabditis elegans. Biology, 2021, 10, 30.	1.3	13
714	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrP ^C binding and downstream pathways. Chemical Science, 2021, 12, 3768-3785.	3.7	6
715	Nanomaterials to target immunity. Advances in Pharmacology, 2021, 91, 293-335.	1.2	3

#	Article	IF	CITATIONS
716	Lipids, beta-secretase 1, and Alzheimer disease. , 2021, , 289-299.		0
717	Interaction between AÎ ² and Tau in the Pathogenesis of Alzheimer's Disease. International Journal of Biological Sciences, 2021, 17, 2181-2192.	2.6	115
718	The search for novel targets in Alzheimer's disease—The 90s redux. Progress in Molecular Biology and Translational Science, 2021, 177, 123-135.	0.9	1
719	Staining and Quantification of β-Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease. Methods in Molecular Biology, 2020, 2144, 211-221.	0.4	5
721	Data Platform for the Research and Prevention of Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2017, 1028, 55-78.	0.8	2
722	Cognitive Impairment and Rehabilitation in Alzheimer's Disease. , 2019, , 1-30.		3
723	Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder. Metabolic Brain Disease, 2021, 36, 67-83.	1.4	23
724	UPLC-Orbitrap HRMS metabolic profiling of Cymbopogon citratus cultivated in Egypt; neuroprotective effect against AlCl3-induced neurotoxicity in rats. Journal of Ethnopharmacology, 2020, 259, 112930.	2.0	18
725	Importance of tau in cognitive decline as revealed by developmental exposure to lead. Toxicology Letters, 2018, 284, 63-69.	0.4	7
726	DNAJ Proteins in neurodegeneration: essential and protective factors. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20160534.	1.8	115
734	A Multi-Modal Deep Learning Approach to the Early Prediction of Mild Cognitive Impairment Conversion to Alzheimer's Disease. , 2020, , .		5
735	Investigation of memory-enhancing botanical mixture and their isolated compounds for inhibition of amyloid-1² and tau aggregation. Applied Biological Chemistry, 2020, 63, .	0.7	4
736	Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor. PLoS ONE, 2016, 11, e0150392.	1.1	15
737	Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PLoS ONE, 2017, 12, e0189413.	1.1	10
738	Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer's Disease. , 2019, 10, 1075.		9
739	Nerve growth factor in brain diseases. Biomedical Reviews, 2019, 29, 1.	0.6	9
740	GSK3β Impairs KIF1A Transport in a Cellular Model of Alzheimer's Disease but Does Not Regulate Motor Motility at S402. ENeuro, 2020, 7, ENEURO.0176-20.2020.	0.9	9
741	Emerging Role of the Cerebrospinal Fluid – Neuronal Interface in Neuropathology. Neuro - Open Journal, 2015, 2, 92-98.	0.1	3

#	Article	IF	CITATIONS
742	Troxerutin protects hippocampal neurons against amyloid beta-induced oxidative stress and apoptosis. EXCLI Journal, 2017, 16, 1081-1089.	0.5	37
743	Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases. Journal of Ophthalmic and Vision Research, 2019, 14, 491-505.	0.7	10
744	D-ribose is elevated in T1DM patients and can be involved in the onset of encephalopathy. Aging, 2019, 11, 4943-4969.	1.4	21
745	Activation of α7 nAChR by PNU-282987 improves synaptic and cognitive functions through restoring the expression of synaptic-associated proteins and the CaM-CaMKII-CREB signaling pathway. Aging, 2020, 12, 543-570.	1.4	27
746	Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. Aging, 2020, 12, 1011-1033.	1.4	48
747	<i>Codonopsis pilosula</i> polysaccharide attenuates AÎ ² toxicity and cognitive defects in APP/PS1 mice. Aging, 2020, 12, 13422-13436.	1.4	33
748	ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice. Aging, 2020, 12, 14819-14829.	1.4	27
749	Careful neuropsychological testing reveals a novel genetic marker, <i>GSTO1*C</i> , linked to the pre-stage of Alzheimer's disease. Oncotarget, 2016, 7, 39108-39117.	0.8	10
750	Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease. Neuroimmunology and Neuroinflammation, 2017, 4, 263.	1.4	17
751	Nutrient-induced Mitochondrial Activation (NiMA): A Novel Lysosome-to-Mitochondria Signaling Pathway Disrupted by Amyloid Oligomers. SSRN Electronic Journal, 0, , .	0.4	1
752	Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders. Current Pharmaceutical Design, 2020, 26, 1277-1285.	0.9	28
753	Increased Susceptibility to Oxidative Death of Lymphocytes from Alzheimer Patients Correlates with Dementia Severity. Current Alzheimer Research, 2014, 11, 1-1.	0.7	26
754	Molecular Basis of Familial and Sporadic Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 952-963.	0.7	241
755	Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy. Current Alzheimer Research, 2019, 16, 710-722.	0.7	39
756	The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. Current Neuropharmacology, 2017, 15, 926-935.	1.4	253
757	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	1.4	12
758	Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 918-931.	0.9	14
759	Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells. Experimental and Therapeutic Medicine, 2017, 13, 3003-3008.	0.8	4

#	Article	IF	CITATIONS
760	Expression levels of the α7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells. Molecular Medicine Reports, 2020, 22, 2063-2075.	1.1	23
761	pFTAA - a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. Neural Regeneration Research, 2015, 10, 1746.	1.6	14
762	Genistein protects hippocampal neurons against injury by regulating calcium/calmodulin dependent protein kinase IV protein levels in Alzheimer's disease model rats. Neural Regeneration Research, 2017, 12, 1479.	1.6	49
763	Neuroprotective effects of statins against amyloid β-induced neurotoxicity. Neural Regeneration Research, 2018, 13, 198.	1.6	31
764	Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease. Indian Journal of Ophthalmology, 2020, 68, 555.	0.5	21
765	Therapeutic Effects of Curcumin on Alzheimer's Disease. Advances in Alzheimer's Disease, 2014, 03, 145-159.	0.3	14
766	Increased processing of SINE B2 ncRNAs unveils a novel type of transcriptome deregulation in amyloid beta neuropathology. ELife, 2020, 9, .	2.8	8
767	Predicting brain atrophy from tau pathology: a summary of clinical findings and their translation into personalized models. Brain Multiphysics, 2021, 2, 100039.	0.8	13
768	Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline. Journal of Alzheimer's Disease, 2021, 84, 1057-1069.	1.2	6
769	Loganin substantially ameliorates molecular deficits, pathologies and cognitive impairment in a mouse model of Alzheimer's disease. Aging, 2021, 13, 23739-23756.	1.4	8
770	The Female Impact in the World of Neurodegeneration. Frontiers in Integrative Neuroscience, 2021, 15, 750603.	1.0	0
771	Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	5.0	131
772	Dementia and the Risk of Periodontitis: A Population-Based Cohort Study. Journal of Dental Research, 2022, 101, 270-277.	2.5	43
773	A Review of miRNAs as Biomarkers and Effect of Dietary Modulation in Obesity Associated Cognitive Decline and Neurodegenerative Disorders. Frontiers in Molecular Neuroscience, 2021, 14, 756499.	1.4	11
774	AuNPs- Aβ-Ni-HRP sandwich assay: A new sensitive colorimetric method for the detection of Aβ 1-40. Talanta, 2022, 237, 122946.	2.9	9
775	Current research status of blood biomarkers in Alzheimer's disease: Diagnosis and prognosis. Ageing Research Reviews, 2021, 72, 101492.	5.0	16
776	Cell death inhibitors protect against brain damage caused by cardiac ischemia/reperfusion injury. Cell Death Discovery, 2021, 7, 312.	2.0	31
777	Protective Effect of Chitosan Oligosaccharide against Hydrogen Peroxide-Mediated Oxidative Damage and Cell Apoptosis via Activating Nrf2/ARE Signaling Pathway. Neurotoxicity Research, 2021, 39, 1708-1720.	1.3	10

#	Article	IF	CITATIONS
778	The Expression and Localisation of G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels Is Differentially Altered in the Hippocampus of Two Mouse Models of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 11106.	1.8	13
780	Sex-Stratified Single-Cell RNA-Seq Analysis Identifies Sex-Specific and Cell Type-Specific Transcriptional Responses in Alzheimer's Disease Across Two Brain Regions. Molecular Neurobiology, 2022, 59, 276-293.	1.9	21
781	Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum. Alzheimer's Research and Therapy, 2021, 13, 167.	3.0	8
782	Merits and Demerits of Vaccination for Patients with Neurological Diseases. Juntendo Medical Journal, 2014, 60, 470-470.	0.1	0
783	Merits and Demerits of Vaccination for Patients with Neurological Diseases. Juntendo Medical Journal, 2014, 60, s53-s59.	0.1	0
784	Frontiers in Clinical Drug Research - Alzheimer Disorders. , 2015, , .		0
785	Organic Disorders of the Brain. , 2016, , 299-324.		0
787	Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer's Disease. , 2018, , .		0
792	Amyloid Beta. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 235-251.	0.1	2
793	Evaluation of Aβ Deposits in the Hippocampus of a Rat Model of Alzheimer's Disease After Intravenous Injection of Human Adipose Derived Stem Cells by Immuno- and Thioflavin S-Costaining. Thrita, 2019, In Press, .	0.4	1
797	Amyloid \hat{l}^2 -peptide interaction with GM1 containing model membrane. Advances in Biomembranes and Lipid Self-Assembly, 2020, 32, 1-24.	0.3	0
798	Salivary Biomarkers in Neurologic Diseases. , 2020, , 121-152.		0
799	Cysteine in Alzheimer's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 326-353.	0.1	0
802	Circadian rhythm and neurodegenerative disorders. Brain Science Advances, 2020, 6, 71-80.	0.3	7
805	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metabolic Brain Disease, 2022, 37, 67-104.	1.4	24
806	Alzheimerâ€~s disease: exploring nature's â€~medicinal chest' for new therapeutic agents. Biomolecular Concepts, 2020, 11, 201-208.	1.0	3
807	Immunotherapy in Neurodegenerative Disorders. , 2021, , 117-136.		0
808	APOE Variants in an Iberian Alzheimer Cohort Detected through an Optimized Sanger Sequencing Protocol. Genes, 2021, 12, 4.	1.0	4

#	Article	IF	CITATIONS
809	Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging. Journal of the Korean Society of Radiology, 2020, 81, 488.	0.1	3
811	The Blood-Brain Barrier in Alzheimer's Disease. Handbook of Experimental Pharmacology, 2020, , 247-266.	0.9	12
812	Autophagic Dysfunction in Neurodegeneration. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 25-62.	0.1	0
814	Preventive Effects of Dairy Products on Dementia and Cognitive Decline. Journal of Dairy Science and Biotechnology, 2020, 38, 27-36.	0.5	0
815	Multiple Causes of Dementia as Engineered Senescence. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	2
816	αS Oligomers Generated from Interactions with a Polyunsaturated Fatty Acid and a Dopamine Metabolite Differentially Interact with Aβ to Enhance Neurotoxicity. ACS Chemical Neuroscience, 2021, 12, 4153-4161.	1.7	10
817	The Correlation Between Olfactory Test and Hippocampal Volume in Alzheimer's Disease and Mild Cognitive Impairment Patients: A Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 755160.	1.7	5
818	Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. American Journal of Psychiatry, 2021, 178, 1014-1025.	4.0	11
819	Mindfulness intervention improves cognitive function in older adults by enhancing the level of miRNA-29c in neuron-derived extracellular vesicles. Scientific Reports, 2021, 11, 21848.	1.6	7
820	Unbiased high-content screening reveals Aβ- and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer's patients and high-pathology controls. PLoS ONE, 2021, 16, e0259335.	1.1	2
821	Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics, 2021, 13, 1897.	2.0	27
822	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 11950.	1.8	7
823	Picomolar-sensitive β-amyloid fibril fluorophores by tailoring the hydrophobicity of biannulated Ï€-elongated dioxaborine-dyes. Bioactive Materials, 2022, 13, 239-248.	8.6	15
824	Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduction and Targeted Therapy, 2021, 6, 379.	7.1	58
826	Increased susceptibility to oxidative death of lymphocytes from Alzheimer patients correlates with dementia severity. Current Alzheimer Research, 2014, 11, 892-8.	0.7	11
827	Protective effect of bone marrow mesenchymal stem cells on PC12 cells apoptosis mediated by TAG1. International Journal of Clinical and Experimental Pathology, 2015, 8, 12093-100.	0.5	2
828	Astrocytes mediated the nootropic and neurotrophic effects of Sarsasapogenin-AA13 via upregulating brain-derived neurotrophic factor. American Journal of Translational Research (discontinued), 2017, 9, 4015-4025.	0.0	1
829	Hypoxia increases amyloid-β level in exosomes by enhancing the interaction between CD147 and Hook1. American Journal of Translational Research (discontinued), 2018, 10, 150-163.	0.0	5

#	Article	IF	CITATIONS
830	TO901317 activation of LXR-dependent pathways mitigate amyloid-beta peptide-induced neurotoxicity in 3D human neural stem cell culture scaffolds and AD mice. Brain Research Bulletin, 2022, 178, 57-68.	1.4	3
831	Nitric Oxide-Dependent Mechanisms Underlying MK-801- or Scopolamine-Induced Memory Dysfunction in Animals: Mechanistic Studies. International Journal of Molecular Sciences, 2021, 22, 12282.	1.8	6
832	Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis. BMC Neurology, 2021, 21, 449.	0.8	7
833	Alleviative Effect of Alpha-Lipoic Acid on Cognitive Impairment in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats. Frontiers in Aging Neuroscience, 2021, 13, 774477.	1.7	12
834	Nuclear pore complex maintenance and implications for age-related diseases. Trends in Cell Biology, 2021, , .	3.6	10
835	Role of Oxygen Radicals in Alzheimer's Disease: Focus on Tau Protein. Oxygen, 2021, 1, 96-120.	1.6	5
836	Causal effect of insulin resistance on small vessel stroke and Alzheimer's disease: A Mendelian randomization analysis. European Journal of Neurology, 2022, 29, 698-706.	1.7	9
837	Structural biology of cell surface receptors implicated in Alzheimer's disease. Biophysical Reviews, 2022, 14, 233-255.	1.5	5
838	An insight into Alzheimer's disease and its on-setting novel genes. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	4
839	Hydroxysafflor Yellow A Inhibits Aβ1–42-Induced Neuroinflammation by Modulating the Phenotypic Transformation of Microglia via TREM2/TLR4/NF-κB Pathway in BV-2 Cells. Neurochemical Research, 2022, 47, 748-761.	1.6	17
840	Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics, 2021, 13, 2049.	2.0	64
841	Lead Exposure in Developmental Ages Promotes Aβ Accumulation by Disturbing Aβ Transportation in Blood-Cerebrospinal Fluid Barrier/Blood–Brain Barriers and Impairing Aβ Clearance in the Liver. Biological Trace Element Research, 2022, 200, 3702-3711.	1.9	5
842	mTORâ€mediated autophagy in the hippocampus is involved in perioperative neurocognitive disorders in diabetic rats. CNS Neuroscience and Therapeutics, 2022, 28, 540-553.	1.9	19
843	Shen-Zhi-Ling oral liquid ameliorates cerebral glucose metabolism disorder in early AD via insulin signal transduction pathway in vivo and in vitro. Chinese Medicine, 2021, 16, 128.	1.6	4
844	Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease. Pharmacological Reviews, 2022, 74, 1-17.	7.1	23
845	A fragment of cell adhesion molecule L1 reduces amyloid-β plaques in a mouse model of Alzheimer's disease. Cell Death and Disease, 2022, 13, 48.	2.7	16
847	Identification of Immune Cells and Key Genes associated with Alzheimer's Disease. International Journal of Medical Sciences, 2022, 19, 112-125.	1.1	19
848	Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2022, 229, 114095.	2.6	13

#	Article	IF	CITATIONS
849	The protective role of exercise against age-related neurodegeneration. Ageing Research Reviews, 2022, 74, 101543.	5.0	47
850	Drug discovery from natural products – Old problems and novel solutions for the treatment of neurodegenerative diseases. Journal of Pharmaceutical and Biomedical Analysis, 2022, 210, 114553.	1.4	19
851	Standpoints in mitochondrial dysfunction: Underlying mechanisms in search of therapeutic strategies. Mitochondrion, 2022, 63, 9-22.	1.6	9
852	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. Current Topics in Behavioral Neurosciences, 2021, , 287-317.	0.8	11
853	Aged Cattle Brain Displays Alzheimer's Disease-Like Pathology and Promotes Brain Amyloidosis in a Transgenic Animal Model. Frontiers in Aging Neuroscience, 2021, 13, 815361.	1.7	3
854	Protective effects of <i>Forsythiae fructus</i> and <i>Cassiae semen</i> water extract against memory deficits through the gut-microbiome-brain axis in an Alzheimer's disease model. Pharmaceutical Biology, 2022, 60, 212-224.	1.3	10
855	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
856	Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials. journal of prevention of Alzheimer's disease, The, 2022, 9, 241-246.	1.5	0
857	Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B, 2022, 12, 1019-1040.	5.7	56
858	Effect of soluble amyloid precursor protein-alpha on adult hippocampal neurogenesis in a mouse model of Alzheimer's disease. Molecular Brain, 2022, 15, 5.	1.3	6
859	Transcriptome and Translatome Regulation of Pathogenesis in Alzheimer's Disease Model Mice. Journal of Alzheimer's Disease, 2022, 86, 365-386.	1.2	3
860	Ultrasoundâ€ŧargeted microbubbles destruction assists dual delivery of betaâ€amyloid antibody and neural stem cells to restore neural function in transgenic mice of Alzheimer's disease. Medical Physics, 2022, 49, 1357-1367.	1.6	6
861	Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database. journal of prevention of Alzheimer's disease, The, 2022, 9, 331-337.	1.5	0
862	Association of small vessel disease with tau pathology. Acta Neuropathologica, 2022, 143, 349-362.	3.9	19
863	Recent Advances in Our Molecular and Mechanistic Understanding of Misfolded Cellular Proteins in Alzheimer's Disease (AD) and Prion Disease (PrD). Biomolecules, 2022, 12, 166.	1.8	8
864	Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2021, 14, 821002.	1.4	10
865	Perspectives on Primary Blast Injury of the Brain: Translational Insights Into Non-inertial Low-Intensity Blast Injury. Frontiers in Neurology, 2021, 12, 818169.	1.1	11
866	Degradation of amyloid peptide aggregates by targeted singlet oxygen delivery from a benzothiazole functionalized naphthalene endoperoxide. Chemical Communications, 2022, 58, 3747-3750.	2.2	5

#	Article	IF	CITATIONS
867	Immunobiology of Gestational Diabetes Mellitus in Post-Medawar Era. Frontiers in Immunology, 2021, 12, 758267.	2.2	12
868	Tau protein aggregation: Key features to improve drug discovery screening. Drug Discovery Today, 2022, 27, 1284-1297.	3.2	12
869	Aesculin offers increased resistance against oxidative stress and protective effects against AÎ ² -induced neurotoxicity in Caenorhabditis elegans. European Journal of Pharmacology, 2022, 917, 174755.	1.7	7
870	The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation. Frontiers in Pharmacology, 2021, 12, 806417.	1.6	24
871	Experience of Western Herbal Medicine practitioners in supporting brain health in mid-life and older patients: A qualitative research study. Journal of Herbal Medicine, 2022, 32, 100547.	1.0	0
872	Lysosomal gene Hexb displays haploinsufficiency in a knock-in mouse model of Alzheimer's disease. IBRO Neuroscience Reports, 2022, 12, 131-141.	0.7	9
873	Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation. Chemical Science, 2022, 13, 2423-2439.	3.7	20
874	Anti-Amyloidogenic and Fibril-Disaggregating Potency of the Levodopa-Functionalized Gold Nanoroses as Exemplified in a Diphenylalanine-Based Amyloid Model. Bioconjugate Chemistry, 2022, 33, 397-410.	1.8	5
875	Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: Implications for Alzheimer's disease therapy. Acta Pharmaceutica Sinica B, 2022, 12, 1707-1722.	5.7	56
876	Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection. Ageing Research Reviews, 2022, 76, 101587.	5.0	28
877	A unifying framework for amyloid-mediated membrane damage: The lipid-chaperone hypothesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140767.	1.1	15
878	Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology. Cell and Bioscience, 2021, 11, 204.	2.1	5
879	The dopamine receptor agonist apomorphine stabilizes neurotoxic αâ€ s ynuclein oligomers. FEBS Letters, 2022, 596, 309-322.	1.3	1
881	Toxicities of amyloid-beta and tau protein are reciprocally enhanced in the Drosophila model. Neural Regeneration Research, 2022, 17, 2286.	1.6	4
882	Rich-Club Organization Disturbances of the Individual Morphological Network in Subjective Cognitive Decline. Frontiers in Aging Neuroscience, 2022, 14, 834145.	1.7	7
883	Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases. Current Medicinal Chemistry, 2022, 29, 4631-4697.	1.2	14
884	Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease, 2022, 85, 1519-1528.	1.2	5
885	Deciphering the Effect of Lysine Acetylation on the Misfolding and Aggregation of Human Tau Fragment 171IPAKTPPAPK180 Using Molecular Dynamic Simulation and the Markov State Model. International Journal of Molecular Sciences, 2022, 23, 2399.	1.8	5

#	Article	IF	CITATIONS
886	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	1.8	5
887	Mechanistic Insights and Therapeutic Delivery through Micro/Nanobubble-Assisted Ultrasound. Pharmaceutics, 2022, 14, 480.	2.0	15
888	Intracerebroventricular Administration of Human Umbilical Cord Blood—Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease. Biomedicines, 2022, 10, 563.	1.4	5
889	Brainâ€Penetration and Neuronâ€Targeting DNA Nanoflowers Coâ€Delivering miRâ€124 and Rutin for Synergistic Therapy of Alzheimer's Disease. Small, 2022, 18, e2107534.	5.2	26
890	Oncogenic Pathways in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 3223.	1.8	9
891	"Drugâ€Carrier―Synergy Therapy for Amyloidâ€ <i>β</i> Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly. Advanced Science, 2022, 9, e2106072.	5.6	15
892	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. International Journal of Molecular Sciences, 2022, 23, 2757.	1.8	10
893	Impact of Chronic Conditions and Dementia in Rural West Texas: A Healthy Aging Study. Journal of Alzheimer's Disease, 2022, , 1-17.	1.2	2
894	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
895	Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. Neurobiology of Aging, 2022, 115, 112-121.	1.5	2
896	Cross-Seeding Controls Al ² Fibril Populations and Resulting Functions. Journal of Physical Chemistry B, 2022, 126, 2217-2229.	1.2	4
897	Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer's disease. Acta Neuropathologica Communications, 2022, 10, 31.	2.4	28
898	Shedding light on biological sex differences and microbiota–gut–brain axis: a comprehensive review of its roles in neuropsychiatric disorders. Biology of Sex Differences, 2022, 13, 12.	1.8	34
899	Intrathecal amyloidâ€beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: A nonhuman primate model of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	5
901	Design, synthesis and biological evaluation of novel <i>N</i> -phosphorylated and <i>O</i> -phosphorylated tacrine derivatives as potential drugs against Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1012-1022.	2.5	11
902	The relationship between body mass index and postoperative delirium. Brain and Behavior, 2022, 12, e2534.	1.0	14
903	Computational design of a β-wrapin's N-terminal domain with canonical and non-canonical amino acid modifications mimicking curcumin's proposed inhibitory function. Biophysical Chemistry, 2022, 286, 106805.	1.5	1
905	Editorial: Degenerative and cognitive diseases. Current Opinion in Neurology, 2022, 35, 208-211.	1.8	0

#	Article	IF	CITATIONS
906	Altered amyloid-Î ² and tau proteins in neural-derived plasma exosomes in obstructive sleep apnea. Sleep Medicine, 2022, 94, 76-83.	0.8	12
907	Characterizing the propagation pathway of neuropathological events of Alzheimer's disease using harmonic wavelet analysis. Medical Image Analysis, 2022, 79, 102446.	7.0	2
908	Decreased expression of protein <i>O</i> -linked mannose β-1,2- <i>N</i> -acetylglucosaminyltransferase 1 contributes to Alzheimer's disease-like pathologies. Journal of Neurophysiology, 2022, 127, 1067-1074.	0.9	1
909	Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review. CNS and Neurological Disorders - Drug Targets, 2023, 22, 255-275.	0.8	4
910	The mouse nicotinamide mononucleotide adenylyltransferase chaperones diverse pathological amyloid client proteins. Journal of Biological Chemistry, 2022, 298, 101912.	1.6	1
911	TAU IMMUNOTHERAPY FOR ALZHEIMER'S (Review Article). Ek'sperimentuli Da Klinikuri Medic'ina, 0, , .	0.0	1
912	Exploration of salient risk factors involved in mild cognitive impairment. European Journal of Neuroscience, 2022, 56, 5368-5383.	1.2	1
913	Therapeutic strategies for tauopathies and drug repurposing as a potential approach. Biochemical Pharmacology, 2022, 198, 114979.	2.0	7
914	Effects of heparan sulfate from porcine mucosa on Aβ1–42-induced neurotoxicity in vitro and in vivo. International Journal of Biological Macromolecules, 2022, 206, 823-836.	3.6	0
915	Are mitophagy enhancers therapeutic targets for Alzheimer's disease?. Biomedicine and Pharmacotherapy, 2022, 149, 112918.	2.5	27
916	Pharmacological evaluation of bromelain in mouse model of Alzheimer's disease. NeuroToxicology, 2022, 90, 19-34.	1.4	9
917	Lingguizhugan decoction protects PC12 cells against Aβ25-35-induced oxidative stress and neuroinflammation by modulating NF-κB/MAPK signaling pathways. Journal of Ethnopharmacology, 2022, 292, 115194.	2.0	10
918	Tyrosine 12 of human calcitonin modulates its amyloid formation, membrane binding, and bioactivity. Biochimie, 2022, 197, 121-129.	1.3	4
919	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
920	Biochanin A alleviates cognitive impairment and hippocampal mitochondrial damage in ovariectomized APP/PS1 mice. Phytomedicine, 2022, 100, 154056.	2.3	14
921	Intraperitoneal Carbamylated erythropoietin improves memory and hippocampal apoptosis in beta amyloid rat model of Alzheimer's disease through stimulating autophagy and inhibiting necroptosis. Physiology and Pharmacology, 2021, .	0.1	1
922	The double $\hat{a} \in \mathbf{e}$ dged sword effect of HDAC6 in A \hat{I}^2 toxicities. FASEB Journal, 2022, 36, e22072.	0.2	2
923	Crude Saponin from Platycodon grandiflorum Attenuates AÎ ² -Induced Neurotoxicity via Antioxidant, Anti-Inflammatory and Anti-Apoptotic Signaling Pathways, Antioxidants, 2021, 10, 1968.	2.2	8

#	Article	IF	CITATIONS
925	Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer's Disease Mouse Models. Frontiers in Cell and Developmental Biology, 2021, 9, 769229.	1.8	5
926	Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer's disease–associated genes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	59
927	Gamma Oscillations in Alzheimer's Disease and Their Potential Therapeutic Role. Frontiers in Systems Neuroscience, 2021, 15, 782399.	1.2	37
928	Sialic Acid Ameliorates Cognitive Deficits by Reducing Amyloid Deposition, Nerve Fiber Production, and Neuronal Apoptosis in a Mice Model of Alzheimer's Disease. NeuroSci, 2022, 3, 28-40.	0.4	1
929	Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?. International Journal of Molecular Sciences, 2021, 22, 13101.	1.8	51
930	High-Phytate Diets Increase Amyloid \hat{I}^2 Deposition and Apoptotic Neuronal Cell Death in a Rat Model. Nutrients, 2021, 13, 4370.	1.7	3
931	What have we learned from past failures of investigational drugs for Alzheimer's disease?. Expert Opinion on Investigational Drugs, 2021, 30, 1175-1182.	1.9	13
932	Brain myelin water fraction is associated with APOE4 allele status in patients with cognitive impairment. Journal of Neuroimaging, 2022, 32, 521-529.	1.0	3
933	Inhibition of scopolamineâ€induced memory and mitochondrial impairment by betanin. Journal of Biochemical and Molecular Toxicology, 2022, 36, e23076.	1.4	5
934	Alzheimer's Disease: A Silent Pandemic – A Systematic Review on the Situation and Patent Landscape of the Diagnosis. Recent Patents on Biotechnology, 2022, 16, .	0.4	0
935	Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics, 2022, 14, 835.	2.0	30
936	The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC. International Journal of Molecular Sciences, 2022, 23, 4253.	1.8	4
937	Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience, 2022, 14, 870517.	1.7	91
938	Phytoplankton Toxins and Their Potential Therapeutic Applications: A Journey toward the Quest for Potent Pharmaceuticals. Marine Drugs, 2022, 20, 271.	2.2	14
939	Coupled Neural–Glial Dynamics and the Role of Astrocytes in Alzheimer's Disease. Mathematical and Computational Applications, 2022, 27, 33.	0.7	1
975	Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19 European Review for Medical and Pharmacological Sciences, 2022, 26, 2201-2214.	0.5	2
976	Myrtenal mitigates streptozotocin-induced spatial memory deficit via improving oxido inflammatory, cholinergic and neurotransmitter functions in mice. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100106.	1.7	4
977	Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer's Disease. Antioxidants, 2022, 11, 829.	2.2	7

#	Article	IF	CITATIONS
978	Evaluation of Inhibitory Activities of Sophora flavescens and Angelica gigas Nakai Root Extracts against Monoamine Oxidases, Cholinesterases, and β-Secretase. Processes, 2022, 10, 880.	1.3	4
979	Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies. Frontiers in Aging Neuroscience, 2022, 14, 838034.	1.7	19
980	The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks. Journal of Alzheimer's Disease, 2022, 87, 1567-1580.	1.2	7
981	NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	1
982	Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer's Disease. Molecular Neurobiology, 2022, 59, 4274-4291.	1.9	7
983	Transgenic Mouse Models of Alzheimer's Disease: An Integrative Analysis. International Journal of Molecular Sciences, 2022, 23, 5404.	1.8	36
984	Macroautophagy in CNS health and disease. Nature Reviews Neuroscience, 2022, 23, 411-427.	4.9	44
985	Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes. Frontiers in Pharmacology, 2022, 13, .	1.6	18
986	Olfactory Evaluation in Alzheimer's Disease Model Mice. Brain Sciences, 2022, 12, 607.	1.1	7
987	Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101636.	5.0	41
988	The role of mitochondrial dysfunction in Alzheimer's disease: A potential pathway to treatment. Experimental Gerontology, 2022, 164, 111828.	1.2	30
989	Brain simulation augments machineâ€learning–based classification of dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	10
990	Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. Neuroscience, 2023, 518, 10-26.	1.1	5
991	Cryptotanshinone Attenuates Amyloid-β42-induced Tau Phosphorylation by Regulating PI3K/Akt/GSK3β Pathway in HT22 Cells. Molecular Neurobiology, 2022, 59, 4488-4500.	1.9	3
992	Effect of disturbances in neuronal calcium and IP3 dynamics on β-amyloid production and degradation. Cognitive Neurodynamics, 2023, 17, 239-256.	2.3	19
994	Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections. Journal of Visualized Experiments, 2022, , .	0.2	1
995	High Intensity Acute Aerobic Exercise Elicits Alterations in Circulating and Skeletal Muscle Tissue Expression of Neuroprotective Exerkines. Brain Plasticity, 2022, 8, 5-18.	1.9	7
996	Predicting the Effects of Repetitive Transcranial Magnetic Stimulation on Cognitive Functions in Patients With Alzheimer's Disease by Automated EEG Analysis. Frontiers in Cellular Neuroscience, 2022, 16, .	1.8	5

#	Article	IF	CITATIONS
997	Shared pathophysiology: Understanding stroke and Alzheimer's disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9
998	From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer's and Parkinson's diseases. Neural Regeneration Research, 2022, 17, 2606.	1.6	17
999	Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. Diagnostics, 2022, 12, 1357.	1.3	2
1002	Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure. Frontiers in Chemistry, 2022, 10, .	1.8	1
1003	TDP-43 drives synaptic and cognitive deterioration following traumatic brain injury. Acta Neuropathologica, 2022, 144, 187-210.	3.9	20
1004	Toxic Effects and Tumor Promotion Activity of Marine Phytoplankton Toxins: A Review. Toxins, 2022, 14, 397.	1.5	20
1005	Transcriptome of the synganglion in the tick Ixodes ricinus and evolution of the cys-loop ligand-gated ion channel family in ticks. BMC Genomics, 2022, 23, .	1.2	4
1006	DHA Ameliorates Cognitive Ability, Reduces Amyloid Deposition, and Nerve Fiber Production in Alzheimer's Disease. Frontiers in Nutrition, 0, 9, .	1.6	9
1007	Coenzyme A-Dependent Tricarboxylic Acid Cycle Enzymes Are Decreased in Alzheimer's Disease Consistent With Cerebral Pantothenate Deficiency. Frontiers in Aging Neuroscience, 0, 14, .	1.7	14
1008	Alzheimer's Disease Connected Genes in the Post-Ischemic Hippocampus and Temporal Cortex. Genes, 2022, 13, 1059.	1.0	5
1009	A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement. European Journal of Medicinal Chemistry, 2022, 239, 114510.	2.6	5
1010	Evolution of Alzheimer's disease research from a health-tech perspective: Insights from text mining. International Journal of Information Management Data Insights, 2022, 2, 100089.	6.5	5
1011	Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update. , 2022, 13, 1092.		14
1012	Mass Spectrometry-Based Proteomic Analysis in Neurodegenerative Disorders' Research. , 2022, , 27-48.		0
1013	The anti-Alzheimer potential of some novel Tacrine-Coumarin Derivatives as a Cholinesterase inhibitor. International Journal of Health Sciences, 0, , 10910-10932.	0.0	0
1014	Protective effects of Liensinine, Isoliensinine, and Neferine on PC12 cells injured by amyloidâ€Î². Journal of Food Biochemistry, 2022, 46, .	1.2	5
1015	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2022, 31, 759-771.	1.9	6
1016	Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain, 2022, 145, 2823-2833.	3.7	22

ARTICLE

1017

IF CITATIONS

1018	Formononetin: A Pathway to Protect Neurons. Frontiers in Integrative Neuroscience, 0, 16, .	1.0	13
1019	Joint Computational/Cell-Based Approach for Screening Inhibitors of Tau Oligomerization: A Proof-of-Concept Study. Journal of Alzheimer's Disease, 2022, 89, 107-119.	1.2	2
1020	Misfolded amyloid-β strains and their potential roles in the clinical and pathological variability of Alzheimer's disease. Neural Regeneration Research, 2023, 18, 119.	1.6	0
1021	Krüppel-like factor 5 accelerates the pathogenesis of Alzheimer's disease via BACE1-mediated APP processing. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
1022	Nanoparticles-based anti-aging treatment of Alzheimer's disease. Drug Delivery, 2022, 29, 2100-2116.	2.5	6
1023	A Review of the Measurement of the Neurology of Gait in Cognitive Dysfunction or Dementia, Focusing on the Application of fNIRS during Dual-Task Gait Assessment. Brain Sciences, 2022, 12, 968.	1.1	4
1024	Development of Î ² -sheet structure in AÎ ² aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140817.	1.1	1
1025	Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer's Disease. Biomedicines, 2022, 10, 1800.	1.4	10
1026	Enhancement of cerebrospinal fluid tracer movement by the application of pulsed transcranial focused ultrasound. Scientific Reports, 2022, 12, .	1.6	11
1027	Investigation of coenzyme Q10 status, serum amyloid-β, and tau protein in patients with dementia. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
1028	Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains. Frontiers in Aging Neuroscience, 0, 14, .	1.7	16
1029	Identification of CNS compatible small molecules as glycogen synthase kinase-3β (GSK-3β) inhibitors through structure-based virtual screening. Medicinal Chemistry Research, 2022, 31, 1545-1557.	1.1	1
1030	Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging. Frontiers in Neuroscience, 0, 16, .	1.4	2
1031	Alzheimer's and Parkinson's disease therapies in the clinic. Bioengineering and Translational Medicine, 2023, 8, .	3.9	37
1032	Statins and cognition: Modifying factors and possible underlying mechanisms. Frontiers in Aging Neuroscience, 0, 14, .	1.7	11
1033	Simulation of disturbances in interdependent calcium and \hat{I}^2 -amyloid dynamics in the nerve cell. European Physical Journal Plus, 2022, 137, .	1.2	21
1034	Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms. Bioengineering and Translational Medicine, 2023, 8, .	3.9	4

Bioavailability of Hesperidin and Its Aglycone Hesperetin—Compounds Found in Citrus Fruits as a Parameter Conditioning the Pro-Health Potential (Neuroprotective and Antidiabetic) Tj ETQq0 0 0 rgBT /Overlock 10.7f 50 733⁄1Td (Activ

#	Article	IF	CITATIONS
1035	Mechanisms of NLRP3 activation and pathology during neurodegeneration. International Journal of Biochemistry and Cell Biology, 2022, 151, 106273.	1.2	9
1036	De novo designed protein inhibitors of amyloid aggregation and seeding. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	32
1037	Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles. Journal of Neurology, 2022, 269, 6613-6626.	1.8	3
1039	Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease. Biomedicines, 2022, 10, 1946.	1.4	14
1040	Alzheimer's genetic risk effects on cerebral blood flow across the lifespan are proximal to gene expression. Neurobiology of Aging, 2022, 120, 1-9.	1.5	3
1041	Alzheimer's Amyloid-β Accelerates Cell Senescence and Suppresses the SIRT1/NRF2 Pathway in Human Microglial Cells. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	1.9	9
1042	Meta-analysis of the effects of palmitic acid on microglia activation and neurodegeneration. , 2023, 2, 281-291.		4
1043	Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	8
1044	Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline across Disease Contexts. Nutrients, 2022, 14, 3231.	1.7	11
1045	EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review. Frontiers in Neuroscience, 0, 16, .	1.4	5
1046	Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells. Chemico-Biological Interactions, 2022, 366, 110126.	1.7	2
1047	NLRP3 inflammasome in neurodegenerative disease. Translational Research, 2023, 252, 21-33.	2.2	25
1048	Methamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies. Biomedicine and Pharmacotherapy, 2022, 154, 113591.	2.5	9
1049	Individualized diagnosis of preclinical Alzheimer's Disease using deep neural networks. Expert Systems With Applications, 2022, 210, 118511.	4.4	4
1050	Impact of aging on the central nervous system: Approaches for antiaging. , 2023, , 403-412.		0
1050 1051	Impact of aging on the central nervous system: Approaches for antiaging. , 2023, , 403-412. Development of Cu(<scp>ii</scp>)-specific peptide shuttles capable of preventing Cu–amyloid beta toxicity and importing bioavailable Cu into cells. Chemical Science, 2022, 13, 11829-11840.	3.7	9
1050 1051 1052	Impact of aging on the central nervous system: Approaches for antiaging., 2023, , 403-412. Development of Cu(<scp>ii</scp>)-specific peptide shuttles capable of preventing Cu–amyloid beta toxicity and importing bioavailable Cu into cells. Chemical Science, 2022, 13, 11829-11840. Alzheimer's disease's tau and amyloid-beta hypothesis - Interplay with the innate immune system, neuroinflammation and gut microbiome. AIP Conference Proceedings, 2022, , .	3.7 0.3	0 9 0
1050 1051 1052 1053	Impact of aging on the central nervous system: Approaches for antiaging., 2023, , 403-412. Development of Cu(<scp>ii</scp>)-specific peptide shuttles capable of preventing Cu–amyloid beta toxicity and importing bioavailable Cu into cells. Chemical Science, 2022, 13, 11829-11840. Alzheimer's disease's tau and amyloid-beta hypothesis - Interplay with the innate immune system, neuroinflammation and gut microbiome. AIP Conference Proceedings, 2022, , . Association of diet quality score with the risk of mild cognitive impairment in the elderly. Nutrition Research and Practice, 2022, 16, 673.	3.7 0.3 0.7	0 9 0 3

#	Article	IF	Citations
1054	Next Generation Cognition-Aware Hearing Aid Devices With Microwave Sensors: Opportunities and Challenges. IEEE Access, 2022, 10, 82214-82235.	2.6	4
1055	Endocytosis in β-amyloid biology and Alzheimerâ \in Ms disease. , 2022, , 111-131.		0
1056	Drug discovery in Alzheimer's disease by regulating autophagy. , 2022, , 263-290.		0
1057	Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease. Food and Function, 2022, 13, 10851-10869.	2.1	5
1058	Natural Therapeutics in Aid of Treating Alzheimer's Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders. Frontiers in Neuroscience, 0, 16, .	1.4	19
1059	Plasma Lipidomics Approach in Early and Specific Alzheimer's Disease Diagnosis. Journal of Clinical Medicine, 2022, 11, 5030.	1.0	8
1060	Connectome-based biophysics models of Alzheimer's disease diagnosis and prognosis. Translational Research, 2023, 254, 13-23.	2.2	1
1061	Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti–β-Amyloid Immunotherapy. Neurology, 2022, 99, .	1.5	13
1062	Membrane interaction to intercellular spread of pathology in Alzheimer's disease. Frontiers in Neuroscience, 0, 16, .	1.4	5
1063	The reduction of astrocytic tau prevents amyloid-Î ² -induced synaptotoxicity. Brain Communications, 2022, 4, .	1.5	2
1064	A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE). Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2395-2402.	2.5	6
1065	An Alzheimer's Disease Mechanism Based on Early Pathology, Anatomy, Vascular-Induced Flow, and Migration of Maximum Flow Stress Energy Location with Increasing Vascular Disease. Journal of Alzheimer's Disease, 2022, , 1-27.	1.2	0
1066	Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments. Neurochemical Research, 2023, 48, 26-38.	1.6	5
1067	Vitis vinifera L. Flavones Regulate Hippocampal Neurons via Autophagy in APP/PS1 Alzheimer Model Mice. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-7.	0.5	1
1068	Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer's mouse model. Frontiers in Aging Neuroscience, 0, 14, .	1.7	8
1069	The Innate and Adaptive Immune Cells in Alzheimer's and Parkinson's Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	9
1070	Different modes of synaptic and extrasynaptic <scp>NMDA</scp> receptor alteration in the hippocampus of <scp>P301S</scp> tau transgenic mice. Brain Pathology, 2023, 33, .	2.1	4
1071	Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment. Frontiers in Immunology, 0, 13, .	2.2	4

<u> </u>		<u> </u>	
(15	ГАТІ	NEDC	DT
	IAL	NLPC	ואר

#	Article	IF	CITATIONS
1072	A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	9
1073	Fasting-mimicking diet cycles reduce neuroinflammation to attenuate cognitive decline in Alzheimer's models. Cell Reports, 2022, 40, 111417.	2.9	15
1074	Inhibition of Glycogen Synthase Kinase and the Neuroprotective Function of Conjugated ZnO-Osthol Nanoparticles in Alzheimer's Disease. Bioinorganic Chemistry and Applications, 2022, 2022, 1-9.	1.8	3
1075	Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer's disease mouse model. Frontiers in Pharmacology, 0, 13, .	1.6	5
1076	Macular Microvascular Density as a Diagnostic Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 139-149.	1.2	5
1077	The effect of Al̂² seeding is dependent on the presence of knock-in genes in the AppNLâ^'Gâ^'F mice. , 0, 1, .		1
1078	Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 × FAD transgenic mouse model of Alzheimer's pathology. Journal of Psychopharmacology, 2022, 1176-1187.	360	1
1080	DNA methylation signatures of Alzheimer's disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. Nature Communications, 2022, 13, .	5.8	35
1082	Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	7
1083	Excretion of Amyloid-Î ² in the Gastrointestinal Tract and Regulation by the Gut Microbiota. Journal of Alzheimer's Disease, 2022, 90, 1153-1162.	1.2	1
1085	New Horizons in Studying the Cellular Mechanisms of Alzheimer's Disease. Future of Business and Finance, 2022, , 51-88.	0.3	0
1086	The Interplay between GSK3β and Tau Ser262 Phosphorylation during the Progression of Tau Pathology. International Journal of Molecular Sciences, 2022, 23, 11610.	1.8	3
1087	An emerging role for stress granules in neurodegenerative disease and hearing loss. Hearing Research, 2022, 426, 108634.	0.9	5
1088	Suppression of Wnt/β-Catenin Signaling Is Associated with Downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer's Disease. Molecular Neurobiology, 0, , .	1.9	4
1089	Preclinical Alzheimer's dementia: a useful concept or another dead end?. European Journal of Ageing, 2022, 19, 997-1004.	1.2	5
1090	Amide proton transfer imaging of Alzheimer's disease and Parkinson's disease. Magnetic Resonance Letters, 2022, , .	0.7	1
1091	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis. Brain Communications, 2022, 4, .	1.5	3
1092	The critical role of the endolysosomal system in cerebral ischemia. Neural Regeneration Research, 2023, 18, 983.	1.6	0

#	Article	IF	CITATIONS
1093	New Possibilities in the Therapeutic Approach to Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 8902.	1.8	14
1094	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. Biomolecules, 2022, 12, 1676.	1.8	24
1095	Recent Progress in Research on Mechanisms of Action of Natural Products against Alzheimer's Disease: Dietary Plant Polyphenols. International Journal of Molecular Sciences, 2022, 23, 13886.	1.8	6
1096	The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer's disease. Phytomedicine, 2022, , 154555.	2.3	2
1097	Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias. Translational Research, 2023, 254, 34-40.	2.2	1
1098	Microglial Piezo1 senses Aβ fibril stiffness to restrict Alzheimer's disease. Neuron, 2023, 111, 15-29.e8.	3.8	37
1099	Alteration in the Synaptic and Extrasynaptic Organization of AMPA Receptors in the Hippocampus of P301S Tau Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 13527.	1.8	5
1100	Role of Probiotics and Diet in the Management of Neurological Diseases and Mood States: A Review. Microorganisms, 2022, 10, 2268.	1.6	21
1101	Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation. ACS Chemical Neuroscience, 2022, 13, 3281-3290.	1.7	7
1103	Recent development of analytical methods for disease-specific protein <i>O</i> -GlcNAcylation. RSC Advances, 2022, 13, 264-280.	1.7	4
1104	The impact of sleep components, quality and patterns on glymphatic system functioning in healthy adults: A systematic review. Sleep Medicine, 2023, 101, 322-349.	0.8	9
1105	Ghrelin system in Alzheimer's disease. Current Opinion in Neurobiology, 2023, 78, 102655.	2.0	2
1106	Protective effects of CCL01 against Aβ-induced neurotoxicity in 5xFAD transgenic mouse model of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2023, 158, 114105.	2.5	6
1107	The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. Bioorganic Chemistry, 2023, 131, 106301.	2.0	35
1108	PROTACS: A technology with a gold rush-like atmosphere. European Journal of Medicinal Chemistry, 2023, 247, 115037.	2.6	9
1109	HMGCS2-Induced Autophagic Degradation of Tau Involves Ketone Body and ANKRD24. Journal of Alzheimer's Disease, 2022, , 1-20.	1.2	3
1110	Development of p-Tau Differentiated Cell Model of Alzheimer's Disease to Screen Novel Acetylcholinesterase Inhibitors. International Journal of Molecular Sciences, 2022, 23, 14794.	1.8	0
1111	Subjective cognitive decline may mediate the occurrence of postoperative delirium by P-tau undergoing total hip replacement: The PNDABLE study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1

			2
#		IF	CITATIONS
1112	concomitant Alzheimer's disease and predicting prognosis. Psychoradiology, 2022, 2, 156-170.	1.0	0
1113	Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. Journal of Alzheimer's Disease, 2023, 91, 43-70.	1.2	7
1114	5'AMP-activated protein kinase: an emerging target of phytochemicals to treat chronic inflammatory diseases. Critical Reviews in Food Science and Nutrition, 0, , 1-26.	5.4	2
1115	Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development. International Journal of Molecular Sciences, 2022, 23, 15036.	1.8	5
1116	Can probiotics mitigate age-related neuroinflammation leading to improved cognitive outcomes?. Frontiers in Nutrition, 0, 9, .	1.6	5
1117	An update on the use of gamma (multi)sensory stimulation for Alzheimer's disease treatment. Frontiers in Aging Neuroscience, 0, 14, .	1.7	12
1118	Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning. BioMedical Engineering OnLine, 2022, 21, .	1.3	0
1119	Hexameric Aggregation Nucleation Core Sequences and Diversity of Pathogenic Tau Strains. Pathogens, 2022, 11, 1559.	1.2	3
1120	Gut Microbiome and Serum Metabolome Profiles of Capsaicin with Cognitive Benefits in APP/PS1 Mice. Nutrients, 2023, 15, 118.	1.7	2
1121	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. Translational Neurodegeneration, 2022, 11, .	3.6	5
1122	Modelling Alzheimer's disease using human brain organoids: current progress and challenges. Expert Reviews in Molecular Medicine, 2023, 25, .	1.6	3
1123	Synthesis, Biological Evaluation, and Docking Studies of Open-Chain Carbohydrate Amides as Acetylcholinesterase Inhibitors. Medicinal Chemistry, 2023, 19, 570-577.	0.7	0
1124	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11
1125	Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status. Medical Science Monitor, 0, 29, .	0.5	3
1126	Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease. Ageing Research Reviews, 2023, 85, 101815.	5.0	6
1127	HIF-1α Causes LCMT1/PP2A Deficiency and Mediates Tau Hyperphosphorylation and Cognitive Dysfunction during Chronic Hypoxia. International Journal of Molecular Sciences, 2022, 23, 16140.	1.8	9
1128	Boosting of tau protein aggregation by <scp> <i>CD40</i> </scp> and <scp> <i>CD48</i> </scp> gene expression in Alzheimer's disease. FASEB Journal, 2023, 37, .	0.2	5
1129	The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review. International Journal of Molecular Sciences, 2023, 24, 1001.	1.8	19

#	Article	IF	Citations
1130	Highly Efficient Singlet Oxygen Generation by BODIPY–Ruthenium(II) Complexes for Promoting Neurite Outgrowth and Suppressing Tau Protein Aggregation. Inorganic Chemistry, 2023, 62, 1102-1112.	1.9	4
1131	Okadaic Acid-Induced Alzheimer's in Rat Brain: Phytochemical Cucurbitacin E Contributes to Memory Gain by Reducing TAU Protein Accumulation. OMICS A Journal of Integrative Biology, 2023, 27, 34-44.	1.0	2
1132	<i>In-silico</i> docking and molecular dynamic introspective study of multiple targets of AChE with Rivastigmine and NMDA receptors with Riluzole for Alzheimer's disease. Journal of Biomolecular Structure and Dynamics, 2023, 41, 12620-12631.	2.0	2
1133	Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer's Disease. , 2023, , 467-481.		0
1135	Acetylcholinesterase inhibition of Alzheimer's disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition. Journal of Biomolecular Structure and Dynamics, 2023, 41, 12532-12544.	2.0	4
1136	Jiedu Yizhi Formula Improves Cognitive Function by Regulating the Gut Dysbiosis and TLR4/NF-κB Signaling Pathway. Neuropsychiatric Disease and Treatment, 0, Volume 19, 49-62.	1.0	1
1137	Sterubin protects against chemically-induced Alzheimer's disease by reducing biomarkers of inflammation- IL-6/ IL-β/ TNF-α and oxidative stress- SOD/MDA in rats. Saudi Journal of Biological Sciences, 2023, 30, 103560.	1.8	8
1138	Gut Microbiota, Alzheimer and Psychiatric Diseases: Unveiling the Relationships and Treatment Options. Healthy Ageing and Longevity, 2023, , 279-333.	0.2	0
1139	Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer's Disease. Cells, 2023, 12, 119.	1.8	12
1140	Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
1141	The Gut Microbiome and Alzheimer's Disease: A Growing Relationship. Current Alzheimer Research, 2022, 19, 808-818.	0.7	4
1142	Dementia risk amongst older adults with hip fracture receiving general anaesthesia or regional anaesthesia: a propensity-score-matched population-based cohort study. British Journal of Anaesthesia, 2023, 130, 305-313.	1.5	12
1144	Wheat ergot fungus-derived and modified drug for inhibition of intracranial aneurysm rupture due to dysfunction of TLR-4 receptor in Alzheimer's disease. PLoS ONE, 2023, 18, e0279616.	1.1	2
1145	A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. Alzheimer's and Dementia, 0, , .	0.4	0
1146	TREM2 Inhibits Tau Hyperphosphorylation and Neuronal Apoptosis via the PI3K/Akt/GSK-3β Signaling Pathway In vivo and In vitro. Molecular Neurobiology, 2023, 60, 2470-2485.	1.9	8
1147	Supporting the Detection of Early Alzheimer's Disease with a Four-Channel EEG Analysis. International Journal of Neural Systems, 2023, 33, .	3.2	1
1148	Altered gene expression in excitatory neurons is associated with Alzheimer's disease and its higher incidence in women. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	1.8	1
1149	Potential Protective Function of AÎ ² ₄₂ Monomer on Tauopathies. Journal of the American Society for Mass Spectrometry, 2023, 34, 472-483.	1.2	1

	CITATION	Report	
#	Article	IF	CITATIONS
1150	The KEAP1-NRF2 system and neurodegenerative diseases. Antioxidants and Redox Signaling, 0, , .	2.5	3
1151	In silico and in vitro analyses of a novel <scp>FoxO1</scp> agonist reducing Aβ levels via downregulation of <scp>BACE1</scp> . CNS Neuroscience and Therapeutics, 2024, 30, .	1.9	2
1152	Partial Destabilization of Amyloid-β Protofibril by Methionine Photo-Oxidation: A Molecular Dynamic Simulation Study. ACS Omega, 2023, 8, 10148-10159.	1.6	1
1153	Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations. Mechanisms of Ageing and Development, 2023, 211, 111787.	2.2	10
1154	The effect of gastric bypass surgery on cognitive function of Alzheimer's disease and the role of GLP1-SGLT1 pathway. Experimental Neurology, 2023, 363, 114377.	2.0	1
1155	In-cell 31P solid-state NMR measurements of the lipid dynamics and influence of exogeneous β-amyloid peptides on live neuroblastoma neuro-2a cells. Biophysical Chemistry, 2023, 297, 107008.	1.5	6
1156	Nature's toolbox against tau aggregation: An updated review of current research. Ageing Research Reviews, 2023, 87, 101924.	5.0	2
1157	Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway. Biomedicine and Pharmacotherapy, 2023, 161, 114473.	2.5	4
1158	Huntingtin as a Presymptomatic Regulator of Alzheimer's Disease. European Medical Journal Neurology, 0, , 29-30.	0.0	0
1159	A Flower-like Brain Targeted Selenium Nanocluster Lowers the Chlorogenic Acid Dose for Ameliorating Cognitive Impairment in APP/PS1 Mice. Journal of Agricultural and Food Chemistry, 2023, 71, 2883-2897.	2.4	3
1160	A peptide rich in glycine–serine–alanine repeats ameliorates Alzheimerâ€ŧype neurodegeneration. British Journal of Pharmacology, 2023, 180, 1878-1896.	2.7	4
1161	Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice. Experimental Neurology, 2023, 362, 114344.	2.0	3
1162	Lipoprotein Metabolism, Protein Aggregation, and Alzheimer's Disease: A Literature Review. International Journal of Molecular Sciences, 2023, 24, 2944.	1.8	2
1163	C/EBPβ/AEP Signaling Drives Alzheimer's Disease Pathogenesis. Neuroscience Bulletin, 0, , .	1.5	0
1164	Digital Intervention for the Management of Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 909-932.	0.7	4
1165	DeepAD: A deep learning application for predicting amyloid standardized uptake value ratio through PET for Alzheimer's prognosis. Frontiers in Artificial Intelligence, 0, 6, .	2.0	2
1166	Huntingtin-associated protein 1-associated intracellular trafficking in neurodegenerative diseases. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
1167	Aza-Residue Modulation of Cyclic <scp>d</scp> , <scp>l</scp> -î±-Peptide Nanotube Assembly with Enhanced Anti-Amyloidogenic Activity. Journal of Medicinal Chemistry, 2023, 66, 3058-3072.	2.9	3

#	Article	IF	CITATIONS
1168	Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target. Frontiers in Aging Neuroscience, 0, 15, .	1.7	11
1169	Using Optogenetics to Model Cellular Effects of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 4300.	1.8	1
1170	Neuroprotective Effect of Combined Treatment with Epigallocatechin 3-Gallate and Melatonin on Familial Alzheimer's Disease PSEN1 E280A Cerebral Spheroids Derived from Menstrual Mesenchymal Stromal Cells. Journal of Alzheimer's Disease, 2023, , 1-16.	1.2	3
1171	Vitamin B6, B12 and folate modulate deregulated pathways and protein aggregation in yeast model of Huntington disease. 3 Biotech, 2023, 13, .	1.1	8
1172	Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer's Disease: A CSF/18F-FDC-PET Study. Biomedicines, 2023, 11, 725.	1.4	1
1173	Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, 92, 1385-1397.	1.2	3
1174	Commentary: A nearly forgotten class of anti-inflammatory lipid molecules in central nervous system. Acta Pharmaceutica Sinica B, 2023, , .	5.7	0
1175	Activity-Based Photoacoustic Probes for Detection of Disease Biomarkers beyond Oncology. ACS Bio & Med Chem Au, 0, , .	1.7	0
1176	Photobiomodulation in Alzheimer's Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?. Pharmaceutics, 2023, 15, 916.	2.0	8
1177	New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 5383.	1.8	7
1178	Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280–acetylated tau in cell and mouse models. Journal of Clinical Investigation, 2023, 133, .	3.9	4
1179	The KEAP1-NRF2 System and Neurodegenerative Diseases. Antioxidants and Redox Signaling, 2023, 38, 974-988.	2.5	17
1180	Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia. International Journal of Molecular Sciences, 2023, 24, 5835.	1.8	4
1181	Oligomerization by co-assembly of \hat{I}^2 -amyloid and $\hat{I}\pm$ -synuclein. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
1182	Current Drug Treatments in Alzheimer's Disease. , 0, 36, 297-302.		0
1183	Therapeutic potential of puerarin against cerebral diseases: From bench to bedside. European Journal of Pharmacology, 2023, 953, 175695.	1.7	4
1184	Nanomaterials disrupting cell-cell junctions towards various diseases. Nano Research, 2023, 16, 7053-7074.	5.8	4
1185	Binding Parameters of [11C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents. Pharmaceuticals, 2023, 16, 495.	1.7	2

#	Article	IF	CITATIONS
1186	JNK Activation in Alzheimer's Disease Is Driven by Amyloid β and Is Associated with Tau Pathology. ACS Chemical Neuroscience, 0, , .	1.7	5
1187	Differential Binding and Conformational Dynamics of Tau Microtubule-Binding Repeats with a Preformed Amyloid-β Fibril Seed. ACS Chemical Neuroscience, 2023, 14, 1321-1330.	1.7	3
1188	Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms. Frontiers in Neuroscience, 0, 17, .	1.4	10
1189	Exploring the therapeutic efficacy of Chlorella pyrenoidosa peptides in ameliorating Alzheimer's disease. Heliyon, 2023, 9, e15406.	1.4	0
1190	Effects of intermittent fasting on cognitive health and Alzheimer's disease. Nutrition Reviews, 2023, 81, 1225-1233.	2.6	11
1191	Metals in Alzheimer's Disease. Biomedicines, 2023, 11, 1161.	1.4	9
1192	Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. Neural Regeneration Research, 2024, 19, 100-115.	1.6	4
1194	Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells. Neural Regeneration Research, 2023, 18, 2633-2637.	1.6	4
1195	Ca2+-Permeable TRPV1 Receptor Mediates Neuroprotective Effects in a Mouse Model of Alzheimer's Disease via BDNF/CREB Signaling Pathway. Molecules and Cells, 2023, 46, 319-328.	1.0	2
1196	Inflammatory Response and Exosome Biogenesis of Choroid Plexus Organoids Derived from Human Pluripotent Stem Cells. International Journal of Molecular Sciences, 2023, 24, 7660.	1.8	1
1215	Trace Elements and Mild Cognitive Impairment. , 2023, , 15-45.		0
1221	Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	49
1222	Regulation of Biomolecular Condensates by Poly(ADP-ribose). Chemical Reviews, 2023, 123, 9065-9093.	23.0	3
1248	Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation. Advances in Neurobiology, 2023, , 3-53.	1.3	0
1261	The Effects and Mechanisms of Xanthones in Alzheimer's Disease: A Systematic Review. Neurochemical Research, 2023, 48, 3485-3511.	1.6	1
1272	Dual Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors: The Quest for a Disease-Modifying Treatment for Alzheimer's Disease. , 2023, , 69-94.		0
1273	Exploring the Role of Tau Proteins in Alzheimer's Disease from Typical Functioning MAPs to Aberrant Fibrillary Deposits in the Brain. , 2023, , 321-349.		0
1275	Current emerging novel therapies for Alzheimer's disease and the future prospects of magneto-mechanical force therapy. Journal of Materials Chemistry B, 2023, 11, 9404-9418.	2.9	0

#	Article	IF	CITATIONS
1303	Stem Cells Vs Exosomes: Promising Therapeutic Approach and Biomarkers Agent against Neurodegenerative Disorders. , 2023, , 169-191.		0
1316	Enhance Early Diagnosis Accuracy ofÂAlzheimer's Disease byÂElucidating Interactions Between Amyloid Cascade andÂTau Propagation. Lecture Notes in Computer Science, 2023, , 66-76.	1.0	0
1330	Nano-imaging agents for brain diseases: Environmentally responsive imaging and therapy. Nano Research, 2023, 16, 13134-13163.	5.8	0
1345	Neurogenesis. , 2023, , .		0
1380	Effect of green tea on human brain health. , 2024, , 301-331.		0
1381	Endogenous molecules in neuroprotection: Acetyl-L-carnitine. , 2024, , 475-491.		Ο
1413	Biochemical and Biophysical Characterization of Tau and α-Linolenic Acid Vesicles In Vitro. Methods in Molecular Biology, 2024, , 193-203.	0.4	0